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Leigh syndrome (LS) is a severe manifestation of mitochondrial disease in children and is
currently incurable. The lack of effective models hampers our understanding of the
mechanisms underlying the neuronal pathology of LS. Using patient-derived induced plur-
ipotent stem cells and CRISPR/Cas9 engineering, we developed a human model of LS caused
by mutations in the complex IV assembly gene SURF1. Single-cell RNA-sequencing and multi-
omics analysis revealed compromised neuronal morphogenesis in mutant neural cultures and
brain organoids. The defects emerged at the level of neural progenitor cells (NPCs), which
retained a glycolytic proliferative state that failed to instruct neuronal morphogenesis. LS
NPCs carrying mutations in the complex I gene NDUFS4 recapitulated morphogenesis
defects. SURF1 gene augmentation and PGC1A induction via bezafibrate treatment supported
the metabolic programming of LS NPCs, leading to restored neuronal morphogenesis. Our
findings provide mechanistic insights and suggest potential interventional strategies for a rare
mitochondrial disease.
https://doi.org/10.1038/s41467-021-22117-z OPEN
1Max Delbrück Center for Molecular Medicine (MDC), Berlin, Germany. 2Department of General Pediatrics, Neonatology and Pediatric Cardiology, Duesseldorf
University Hospital, Medical Faculty, Heinrich Heine University, Duesseldorf, Germany. 3 Berlin Institute for Medical Systems Biology (BIMSB), Max Delbrück
Center for Molecular Medicine (MDC), Hannoversche Str 28, 10115, Berlin, Germany. 4 Institute of Genetics and Animal Biotechnology, Polish Academy of
Sciences, Jastrzebiec, n/Warsaw, Magdalenka, Poland. 5 Emory University, Atlanta, GA, USA. 6Department of Diagnostics and Public Health, University of
Verona, Verona, Italy. 7Mitochondrial Medicine Laboratory, Department of Medical Biotechnology and Translational Medicine, University of Milan, Milan, Italy.
8Unit of Medical Genetics and Neurogenetics Fondazione IRCCS Istituto Neurologico “Carlo Besta”, Milan, Italy. 9 Charité - Universitätsmedizin Berlin,
Department of Neurology, Berlin, Germany. 10Charité - Universitätsmedizin Berlin, Department of Neuropsychiatry, Berlin, Germany. 11Max Planck Institute for
Molecular Genetics, Berlin, Germany. 12Charité - Universitätsmedizin Berlin, Department of Neuropediatrics, Berlin, Germany. 13University Children’s Hospital,
Paracelsus Medical University (PMU), Salzburg, Austria. 14 Radboud Center for Mitochondrial Medicine, Department of Pediatrics, Amalia Children’s Hospital,
Radboudumc, Nijmegen, The Netherlands. 15University of Edinburgh and UK DRI, Edinburgh, UK. 16Department of Psychiatry and Psychotherapy, Klinikum rechts
der Isar, Technical University Munich, Munich, Germany. 17Charité – Universitätsmedizin, Department of Neuropathology, Berlin, Germany. 18 Berlin Institute of
Health (BIH), Berlin, Germany. 19NeuroCure Clinical Research Center, Berlin, Germany. ✉email: rajewsky@mdc-berlin.de; markus.schuelke@charite.de;
alessandro.prigione@hhu.de









M itochondrial disease represents the largest class ofinborn errors of metabolism mainly comprisingmonogenic disorders that disrupt oxidative phosphor-
ylation (OXPHOS)1. The most severe pediatric manifestation of
mitochondrial disease is Leigh syndrome (OMIM #256000)2.
Leigh syndrome (LS) affects 1 in 36,000 newborns3 and causes
lactic acidosis and symmetric lesions in the central nervous sys-
tem (CNS), predominantly of basal ganglia and brainstem, lead-
ing to intellectual disability and muscle weakness with a peak of
mortality before three years of age4. Mutations in more than 75
genes of nuclear or mitochondrial DNA (mtDNA) can cause LS5.
The most commonly affected mitochondrial complexes in LS are
complex I (CI) and complex IV (CIV)6.
One of the most frequently mutated nuclear genes in LS is the
SURF1 gene (Surfeit locus protein 1, NM_003172.2)7–9. SURF1
gene contains 9 exons, is located on chromosome 9q34, and
encodes a protein that is highly conserved among eukaryotes and
prokaryotes10. SURF1 protein is located in the mitochondrial inner
membrane and is involved in the assembly of CIV, i.e., the cyto-
chrome c oxidase (COX) (Fig. 1a). SURF1 appears particularly
important for the assembly of mtDNA-encoded proteins MT-CO1,
MT-CO2, and MT-CO3, which constitute the catalytic core of
COX11,12. When the stability of this active COX site is impaired,
the whole COX assembly can be compromised13,14. Accordingly,
SURF1 mutations lead to defective COX assembly15,16, the absence
of SURF1 or its yeast homolog Shy1 cause severe COX
deficiency8,17, and fibroblasts and muscle fibers carrying SURF1
mutations display decreased COX activity7,8,16.
There are no FDA-approved drugs to treat mitochondrial
disease, and the pathophysiological mechanisms underlying the
CNS defects are poorly understood18,19. One major obstacle for
treatment development is the lack of effective model systems
recapitulating the human disease course18,19. This is particularly
the case for SURF1 mutations20. Surf1 knock-out mice failed to
develop LS-like neurological phenotypes and showed prolonged
lifespan21,22. CNS-specific knock-down of Surf1 in flies
caused COX deficiency but no neurological alterations23. Surf1
knock-down in zebrafish led to developmental defects mainly in
endodermal tissue and peripheral nervous system24. Surf1 knock-
out in piglets resulted in a severe lethal phenotype with CNS
developmental delay without overt neurodegeneration and no
apparent COX deficiency25. These species-specific differences
underscore the possibility that human cells are more dependent
on SURF1 function for COX assembly than those of other species.
In fact, key differences in COX expression and assembly have
been observed in fibroblasts from SURF1 patients compared to
fibroblasts from Surf1 knock-out mice26,27.
Recent studies generated induced pluripotent stem cells (iPSCs)
from LS patients carrying mtDNA mutations in the mitochondrial
complex V (CV) gene MT-ATP6 or the CI gene MT-ND5. LS
patient-derived neural cells showed defective bioenergetics28,29,
decreased protein synthesis30, impaired mitochondrial calcium
homeostasis29,31, and abnormal corticogenesis32. However, the
molecular pathophysiology of LS caused by SURF1 mutations
remains to be elucidated.
We applied patient-specific iPSCs and CRISPR/Cas9 technology
to investigate the mechanisms underlying the neuronal pathology
caused by SURF1 mutations. Single-cell transcriptomics and multi-
omics analysis of mutant two-dimensional (2D) neural cultures
and three-dimensional (3D) cerebral organoids pointed toward a
defect of early neuronal morphogenesis. Mutant neural progenitor
cells (NPCs) were unable to shift toward OXPHOS and retained a
proliferative glycolytic state that failed to instruct morphogenesis.
Morphogenesis defects were recapitulated in neural cells
carrying mutations in the nuclear CI gene NDUFS4 (NADH
dehydrogenase [ubiquinone] iron-sulfur protein 4, NM_002495.2),
another frequent cause of LS6,33,34 that has not been studied so far
using iPSCs.
Interventions that boosted the metabolic shift of NPCs, such as
lentivirus-mediated and adeno-associated virus (AAV)-mediated
SURF1 gene augmentation and stimulation of mitochondrial
biogenesis via bezafibrate treatment or PGC1A overexpression,
restored early neuronal morphogenesis. Our findings suggest that
dysfunctional neuronal wiring could be at the basis of the neu-
rodevelopmental defects seen in LS, and indicate potential
intervention strategies for this incurable mitochondrial disease in
children.
Results
Generation of an iPSC-based model of LS caused by SURF1
mutations. We obtained skin fibroblasts from two LS patients
belonging to two distinct consanguineous families carrying
homozygous mutations in SURF1 (Fig. 1a, b). Patient S1 harbored
a c.530T>G p.(V177G) mutation (Supplementary Fig. 1a-b),
while patient S2 carried a c.769G>A p.(G257R) mutation
(Supplementary Fig. 1c-d). Among the two mutations, c.769G>A
led to a more clinically severe phenotype and was reported to be
the most common variant observed in LS patients in the Turkish
community35 to which both patient families belonged.
We generated SURF1 iPSCs (S1 and S2) with Sendai viruses
(Supplementary Fig. 1e–i). We used clustered regularly inter-
spaced short palindromic repeats (CRISPR) and high-fidelity
Cas9 (eCas9), which has limited off-target effects36, to correct the
more severe mutation c.769G>A (p.G257R) on both alleles of S2
iPSCs. We generated isogenic iPSC lines that did not carry the
mutation within the patient’s genetic background (SURF1_No-
Mut) (Fig. 1c). We generated three isogenic SURF1_NoMut lines:
S2_Corr1, S2_Corr2, and S2_Corr3 (Supplementary Fig. 2c-d).
We increased the efficiency of knock-in events by promoting
homologous direct repair (HDR) and inhibiting non-homologous
end joining by co-transfecting plasmids expressing RAD52 and
dominant-negative p53-binding protein 1 (dn53BP1)37 (Supple-
mentary Fig. 2a). In the HDR template, we introduced two silent
mutations that we could trace to confirm template integration
(Fig. 1c, Supplementary Fig. 2b). Using the same guide RNAs
(gRNAs) and approach, we further targeted the more severe
c.769G>A mutation. We introduced the c.769G>A mutation into
both alleles of control (CTL) iPSCs (line C1) to generate iPSC
lines that carried the mutation in a control healthy background
(CTL_Mut) (Fig. 1c, Supplementary Fig. 2b). We obtained two
isogenic CTL_Mut lines: C1_Mut1 and C1_Mut2.
We confirmed that genetically engineered iPSC lines (SURF1_-
NoMut and CTL_Mut) maintained their pluripotent identity
(Supplementary Fig. 2e) and retained a normal karyotype
(Supplementary Fig. 2f-g). We performed whole-genome sequen-
cing (WGS) of S2 iPSCs and S2_Corr1 iPSCs. We used the
CRISPR Gold algorithm to predict off-target effects and then
interrogated the WGS datasets accordingly. We confirmed the
absence of unintended events (top 58 predicted off-target sites) in
S2_Corr1 compared to S2, demonstrating the reliability of our
genome editing approach (Supplementary Data 1).
Altogether, we generated two sets of complementary isogenic
iPSC lines. The first isogenic set carried the SURF1 mutation
c.769G>A either in a healthy genetic background (CTL_Mut)
or in a patient-specific genetic background (SURF1_Mut).
The second isogenic set was mutation-free either in a healthy
genetic background (CTL_NoMut) or in a patient-specific
genetic background (SURF1_NoMut). This genome engineering
approach would enable us to dissect the specific impact of the
SURF1 mutation on the disease pathogenesis irrespective of any
potential effects due to the nuclear or mitochondrial genomic
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Fig. 1 Generation of an iPSC-based model of LS due to SURF1 mutations. a Mitochondrial respiratory chain and putative SURF1 function in CIV assembly.
MM mitochondrial membrane, IMM inner mitochondrial membrane, IMS intermembrane space. b Electropherograms showing 5′ > 3′ sequences of SURF1
in iPSCs from patients S1 and S2 carrying the mutations c.530T > G p.(V177G) and c.769G > A p.(G257R), respectively. Orange stars: mutation site.
c Genome editing approach to correct mutation c.769G > A in patient line S2, and to introduce the same mutation in control line C1. Orange stars: mutation
site; blue stars: correction site; black underlines: artificially introduced silent mutations; gRNA: guide RNA; HDR: homology direct repair. d Overview of iPSC
lines used in this study. e Immunoblot of MT-CO2 (26 kDa) in NPCs derived from hESCs (H1), CTL (CTL_NoMut: C2, C1; SURF1_NoMut: S2_Corr1,
S2_Corr2), and SURF1 (SURF1_Mut: S1, S2) (n= 2 independent experiments). f One dimensional (1D) blue-native gel electrophoresis (BNGE) analysis of
mitochondrial complexes showing lack of incorporation of MT-CO2 into CIV in NPCs from CTL (CTL_NoMut: C1) and SURF1 (CTL_Mut: C1_Mut1). The
structure of the complex II (CII) (visualized by SDHA antibody) was not affected (n= 2 independent experiments). g Two-dimensional (2D) BNGE showing
mitochondrial complex assembly in NPCs from CTL (CTL_NoMut: C1) and SURF1 (CTL_Mut: C1_Mut1). Red arrows: structurally impaired CIV migrating at
lower molecular weight (detected by MT-CO1 and COX4I1 antibodies); red arrowhead: accumulation of COX assembly intermediates (detected by MT-
CO1 antibody); open red arrowheads: loss of III2+ IV supercomplex (detected by COX4I1 and UQCRC2 antibodies). We used CIII (detected by UQCRC2
antibody) and CII (detected by SDHB antibody) to align CTL blot with SURF1 blot (n= 2 independent experiments). h, i Quantification and representative
images of COX activity intensity in CTL NPCs (CTL_NoMut: C1, C2, C3; SURF1_NoMut: S2_Corr1, S2_Corr2) and SURF1 NPCs (SURF1_Mut: S1, S2;
CTL_Mut: C1_Mut1) (mean ± s.e.m.; each dot represents a biological replicate; n= 10 biological replicates per line over three independent experiments;
****p < 0.0001 CTL vs. SURF1; two-sided Mann–Whitney U test). Scale bar: 500 nm.
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backgrounds, whose interplay has been suggested to contribute to
the development of mitochondrial disorders38.
We grouped our samples into “controls” (CTL) and “diseased”
(SURF1). The CTL group included (i) CTL_NoMut lines that we
derived from healthy individuals (C1, C2, C3) and (ii)
SURF1_NoMut lines that we generated by correcting the
c.769G>A mutation in both alleles of patient S2 iPSCs (S2_Corr1,
S2_Corr2). The SURF1 group included (i) SURF1_Mut lines that
we derived from LS patients (S1, S2) and (ii) CTL_Mut lines that
we obtained by introducing the c.769G>A mutation into both
alleles of control C1 iPSCs (lines C1_Mut1, C1_Mut2) (Fig. 1d).
We focused our further study on corrected lines S2_Corr1 and
S2_Corr2, and on mutant line C1_Mut1.
We investigated the biochemical validity of our model by
testing the assembly and functionality of COX in iPSC-derived
NPCs. MT-CO2 protein was expressed in NPCs from healthy
controls (CTL_NoMut: C1, C2), from human embryonic stem
cells (hESCs: H1), and from genetically corrected iPSCs
(SURF1_NoMut: S2_Corr1, S2_Corr2) (Fig. 1e). We could not
detect MT-CO2 protein in patient-derived NPCs (SURF1_Mut:
S1, S2) (Fig. 1e). The absence of a band in SURF1 NPCs suggested
a rapid degradation of free MT-CO2 that was not assembled
into COX. Blue-native gel electrophoresis (BNGE) confirmed
the absence of MT-CO2 protein in the catalytic core of CIV in
NPCs carrying the SURF1 mutation in a healthy background
(CTL_Mut: C1_Mut1) (Fig. 1f). 2D BNGE confirmed that the
introduction of the mutation into control NPCs (CTL_Mut:
C1_Mut1) was sufficient to decrease the amount of fully-
assembled CIV, leading to a partially assembled complex
migrating at lower molecular weight (Fig. 1g, red arrows). SURF1
NPCs (CTL_Mut: C1_Mut1) also accumulated assembly inter-
mediates containing MT-CO1 (Fig. 1g, red arrowhead). The
impairment of CIV assembly prevented the formation of the
supercomplex composed by complex III (CIII) and CIV (III2+
IV, detected by COX4I1 and UQCRC2 antibodies) (Fig. 1g, open
red arrowheads), while the individual assembly of complex II
(CII) and CIII was unaffected (Fig. 1g). The findings are in
agreement with the reported functional defects of CIV assembly
caused by SURF1 mutations15,26.
We next assessed the enzyme activity of the COX complex
using in situ enzyme analysis. We observed normal COX activity
in NPCs from CTL (CTL_NoMut: C1, C2, C3; SURF1_NoMut:
S2_Corr1, S2_Corr2). Conversely, COX activity was dramatically
reduced and almost undetectable in SURF1 NPCs (SURF1_Mut:
S1, S2; CTL_Mut: C1_Mut1) (Fig. 1h, i). The enzyme activity of
CII (succinate dehydrogenase, SDH) was similar in all NPCs
(Supplementary Fig. 2h). The findings confirmed that SURF1
mutations irrespective of the genomic background impair the
activity of COX without affecting the activity of other complexes.
Taken together, the developed iPSC-based model of LS caused
by SURF1 mutations recapitulated the disease defects at the
biochemical level.
SURF1 mutations impair neuronal maturation. We set out to
use the newly generated LS model to address the pathogenic
effects of SURF1 mutations on the development of human neu-
rons. We first employed a 2D differentiation protocol (Fig. 2a)
generating differentiated neurons (DNs) enriched for dopami-
nergic tyrosine hydroxylase (TH)-positive neurons39 (Supple-
mentary Fig. 3a-b), whose degeneration contributes to the basal
ganglia pathology of LS40. DN cultures contained also astrocytes
(Supplementary Fig. 3c-d) that are an important CNS source of
lactate, whose levels are increased in LS4. We compared SURF1
DNs (SURF1_Mut: S1, S2; CTL_Mut: C1_Mut1) to CTL DNs
(CTL_NoMut: C1, C2, C3; SURF1_NoMut: S2_Corr1, S2_Corr2).
We used DNs derived from hESC line H1 to ensure that our
control iPSCs were behaving similarly to the “gold standard” of
pluripotent stem cells.
SURF1 DNs at 4 weeks (4w) and 8 weeks (8w) showed reduced
numbers of TUJ1-positive neurons compared to control DNs
(Fig. 2b). In agreement with the presence of COX impairment
(Fig. 1h, i), SURF1 DNs had a reduction of oxygen consumption
rate (OCR), maximal respiration, and ATP production rate
compared to CTL DNs (Fig. 2c, d, Supplementary Fig. 3e–h). All
DN cultures showed electrophysiological maturation (Supple-
mentary Fig. 3j–l) and higher amount of secreted cytokines over
time (Supplementary Fig. 3i). However, neuronal maturation
appeared defective in SURF1 DNs, which exhibited reduced
sodium and potassium currents at 4w and 8w compared to CTL
DNs (Fig. 2e, f). SURF1 DNs also lacked repetitive spiking and
postsynaptic currents (Fig. 2g), and contained higher numbers of
non-spiking neurons (Supplementary Fig. 3m).
We next investigated whether neuronal maturation defects
could be recapitulated in 3D. We derived cortical brain
organoids41,42, and analyzed them after 40 days (D40) and
90 days (D90), which may correspond to weeks 12 and 16
post-conception43 (Fig. 2h and Supplementary Data 2). We
compared SURF1 organoids (SURF1_Mut: S1, S2; CTL_Mut:
C1_Mut1) to CTL organoids (CTL_NoMut: C1, C2; SURF1_-
NoMut: S2_Corr1, S2_Corr2) (Supplementary Data 2). The
presence of TUJ1-positive and synaptophysin (SYP)-positive
neurons was reduced in D40 SURF1 organoids compared to CTL
organoids (Fig. 2i, Supplementary Fig. 3n), suggesting aberrant
neuronal development in mutants. The defective neuronal
maturation of mutant cells became more evident at D90, as
seen by the further reduction of TUJ1-positive, MAP-positive,
and SYP-positive neurons in SURF1 organoids compared to CTL
organoids (Fig. 2i).
Collectively, 2D and 3D cultures indicated that SURF1
mutations disrupted human neuronal maturation.
Single-cell transcriptomics identifies defective acquisition of
mature neural fate in SURF1-mutant 2D and 3D cultures. To
elucidate the impact of SURF1 mutations on neuronal generation,
we investigated the cellular composition of 2D and 3D cultures
using droplet-based single-cell RNA-sequencing. We analyzed the
single-cell transcriptome of 4w DNs from CTL (CTL_NoMut: C1;
SURF1_NoMut: S2_Corr1) and SURF1 (SURF1_Mut: S2). We
observed a clear separation between control and mutant popu-
lations in the uniform manifold approximation and projection
(UMAP)44 dimensionality reduction plot (Fig. 3a). K-nearest
neighbors based clustering of DN-derived single cells identified
seven clusters (Fig. 3b, Supplementary Data 3).
Control DNs populated clusters 1, 2, 3, 4, and 5 (Fig. 3b, c).
Clusters 1 and 4 were enriched in cells with progenitor and glial
identity expressing genes associated with progenitors (PTPRZ1,
PTN) and astrocytes (SLC1A3, also known as GLAST1, SOX9,
S100B, DLK1) (Fig. 3c, Supplementary Data 3). Clusters 2, 3, and
5 were composed of cells with gene signature related to neurite
outgrowth (ROBO3, NEFM), control of proliferation (MEG3,
MEIS2), and neuronal maturation (DCX, ANK2, NSG2, STMN2)
(Fig. 3c, Supplementary Data 3).
SURF1 DNs populated clusters 0, 6, and 7 (Fig. 3b, c). Cluster 0
and 6 were enriched in cells expressing genes related to cell cycle
and cancer-associated proliferation (SFRP2, CENPF, TOP2A,
UBE2C, CRABP2, MYC) (Fig. 3c, Supplementary Data 3). Cluster
7 included cells with aberrant neuronal identity that expressed
neuronal development genes (NEFM, DCX, STMN2, HES6) but
also cell cycle and cancer-related genes (CRABP2, CCND1, MYC)
(Fig. 3c, Supplementary Data 3). In accordance with a failed
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acquisition of neuronal and glial fate, the distribution of cell cycle
stages of SURF1 DNs was suggestive of enhanced proliferation,
with higher number of cells in G2M and S2 phase compared to
CTL DNs (Fig. 3d, e, Supplementary Fig. 4a). Accordingly, cells
expressing proliferative markers (MYC, TOP2A) clustered mainly
within SURF1-mutant population (Fig. 3f, g).
We next profiled the single-cell transcriptome of 3D brain
organoids at D90 from CTL (CTL_NoMut: C1; SURF1_NoMut:
S2_Corr1) and SURF1 (SURF1_Mut: S2). CTL and SURF1
organoids showed a clearly defined separation (Fig. 3h,
Supplementary Fig. 4b). k-nearest neighbors based clustering
of organoids-derived single cells identified 13 clusters (Fig. 3i,
Supplementary Data 3).
CTL organoids populated clusters 2, 4, 6, 7, 8, 10, and 12 (Fig. 3i,
j). Cluster 2, 8, and 12 contained cells with gene signature indicative
of choroid plexus (TTR, CXCL14), hypothalamic and diencephalon
neurons (PMCH, PCP4, RSPO3), apical radial glia (ANXA1,









































































































































b c d4w DNs
****


























































































































Fig. 2 SURF1 mutations impair neuronal maturation in 2D and 3D cultures. a 2D differentiation into mature differentiated neurons (DNs). We analyzed
DNs at 4 weeks (4w) and 8 weeks (8w) starting from NPCs. b HCA quantification of TUJ1+ neurons in 4w and 8w DNs from CTL (CTL_NoMut: C1, C2,
C3; SURF1_NoMut: S2_Corr1, S2_Corr2) and SURF1 (SURF1_Mut: S1, S2; CTL_Mut: C1_Mut1) (mean ± s.e.m.; each dot represents a biological replicate; n=
20 biological replicates per line over three independent experiments; **p= 0.0013, ****p < 0.0001 CTL vs. SURF1; two-sided Mann–Whitney U test).
c, d Bioenergetics of 4w DNs and 8w DNs from CTL (CTL_NoMut: C1, C2, C3; SURF1_NoMut: S2_Corr1, S2_Corr2) and SURF1 (SURF1_Mut: S1, S2;
CTL_Mut: C1_Mut1) (mean ± s.e.m.; each dot represents a biological replicate; n= 20 biological replicates per line over three independent experiments;
****p < 0.0001 CTL vs. SURF1; two-sided Mann–Whitney U test). e, f Sodium (below x axis) and potassium (above x axis) currents in 4w and 8w DNs from
CTL (CTL_NoMut: C1, C2, C3; SURF1_NoMut: S2_Corr1, S2_Corr2) and SURF1 (SURF1_Mut: S1, S2; CTL_Mut: C1_Mut1) (mean ± s.d.; n= 40 individual cells
per line over three independent experiments; ***p < 0.001, ****p < 0.0001 CTL vs. SURF1; one-way ANOVA followed by Bonferroni multiple comparison
test). g Electrophysiology traces in current-clamp recordings for 8w DNs from CTL (SURF1_NoMut: S2_Corr1) and SURF1 (SURF1_Mut: S2). Above: spiking
activity; below: spontaneous postsynaptic activity; stars: glutamatergic postsynaptic currents. h 3D differentiation into cerebral organoids. We counted
days of differentiation starting from embryoid bodies (EBs). i Cerebral organoids from CTL (SURF1_NoMut: S2_Corr1) and SURF1 (SURF1_Mut: S2) at D40
and D90. Reproduced in CTL (CTL_NoMut: C1, C2) and SURF1 (SURF1_Mut: S1; CTL_Mut: C1_Mut1) (3–8 organoids per line per experiment, n= 3
independent experiments). Scale bars: 100 µm.
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Supplementary Data 3). Cluster 4 and 7 comprised cells expressing
genes associated with neural progenitors (PAX6, LHX2, FABP7,
PTN, GPM6B) and outer radial glia (FAM107A, PTPRZ1) (Fig. 3j,
Supplementary Data 3). Cluster 6 and 10 included cells expressing
neuronal markers (FOXG1, DCX, SMNT4, NFIB, NSG2, SYT1)
(Fig. 3j, Supplementary Data 3).
SURF1 organoids populated clusters 0, 1, 3, 5, 9, 11, and 13
(Fig. 3i, j). Cluster 0, 1, 3, and 11 contained cells expressing
proliferative and cell cycle genes (CRABP1, SFRP1, MYC, TOP2A,
UBE2C, PRTG), and pluripotency-associated genes (LIN28A,
DPPA4, POU5F1, USP44) (Fig. 3j, Supplementary Data 3). Cells
in cluster 5 resembled those in cluster 7 of DNs, and included cells
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-021-22117-z
6 NATURE COMMUNICATIONS |         (2021) 12:1929 | https://doi.org/10.1038/s41467-021-22117-z | www.nature.com/naturecommunications
with aberrant neuronal identity that expressed neuronal genes
(GAP43, NEFM, DCX, HES6) and cancer-related proliferative
genes (CRABP1, MYC, SFRP1) (Fig. 3c, Supplementary Data 3).
Cluster 9 and cluster 13 comprise non-neuronal cells expressing
markers of neuroepithelial (COL3A1, LUM) and mesodermal
identity (MYLPF, TTN) (Fig. 3c, Supplementary Data 3). Con-
gruent with a failure of proper glial and neuronal maturation, cell
cycle stage distribution of SURF1 organoids showed increased cells
in G2M and S2 stages and fewer cells in G1 stage compared to
CTL organoids (C1, S2_Corr1) (Fig. 3k, l, Supplementary Fig. 4a).
SURF1 organoids were in fact enriched for cells expressing
proliferative markers (MYC, TOP2A) (Fig. 3m, n).
Altogether, single-cell transcriptomics suggested that SURF1
mutations disrupted neuronal maturation by causing an imbal-
ance between proliferation and differentiation.
Multi-omics analysis reveals aberrant control of metabolism,
proliferation, and morphogenesis in SURF1 neural cultures.
We next aimed to gain insights into the mechanisms underlying the
SURF1 mutation-induced failure in controlling cell proliferation
during neuronal generation. We carried out multi-omics analysis of
8w DNs from CTL (SURF1_NoMut: S2_Corr1) and SURF1
(SURF1_Mut: S2) (Fig. 4a). We integrated total RNA-sequencing
(Supplementary Fig. 4c-d, Supplementary Data 5), proteomics
(Supplementary Data 6-7), and metabolomics (Supplementary
Data 8) using xMWAS, a software for integration of multiple omics
platforms45. xMWAS identified three communities composed
of tightly connected genes, protein, and metabolites (Fig. 4b, Sup-
plementary Data 4).
Enriched pathways in community 1 were related to signaling
and morphogens (Fig. 4b, Supplementary Data 4). Disrupted
signaling pathways included TGFβ pathway (TGFBR1, NODAL,
LEFTY2, IGF2BP1), WNT pathway (DKK3, SFRP2, WNT7B), and
sonic hedgehog (SHH) (Fig. 4c, d).
Community 2 was enriched in metabolic pathways (community
2 contained 80 metabolic pathways, while community 1 contained
28 and community 3 contained 45) (Fig. 4b, Supplementary
Data 4). Downregulated genes and proteins in SURF1 DNs involved
mitochondrial bioenergetics (MT-CO3, PDK4, PPARGC1A) (Fig. 4c,
d, Supplementary Fig. 4f). Downregulated proteomics-related
pathways included electron transport chain (Supplementary Fig. 4h).
Downregulated metabolites included carnitine, choline, xanthine,
and energy-related molecules AMP, ADP, and ATP (Fig. 4e). We
also observed signs of altered nicotinamide adenine dinucleotide
(NAD) metabolism in SURF1 DNs, as shown by low amount of
NAD and NADP (Fig. 4e) and low expression of enzymes involved
in NAD and NADP metabolism (NAMPT, GPD1, G6PD1) (Fig. 4c,
d, Supplementary Data 5). Interestingly, low NADP was identified
as part of the metabolic signature of LS46 and exogenous NAD+
rescued the cell death induced by glucose-by-galactose replacement
in fibroblasts derived from LS patients carrying CI mutations47.
Within community 2, we also identified increased expression of
regulators of cell proliferation (CENPE, MKI67, TOP2A, UBE2C,
guanine), cancer, and pluripotency (DNMT3B, DPPA4, MYC,
POU5F1, CRABP2) (Fig. 4c–e). Upregulated proteomics-related
pathways in SURF1 DNs included DNA replication (Supplemen-
tary Fig. 4h), and DNA and chromosome-related cell compartments
(Supplementary Fig. 4g). Upregulated metabolites included
glycolysis-related metabolites, like D-fructose 2,6-bisphosphate
(2FDP) and 2-phosphodiglyceric acid (2PDG) (Fig. 4e).
Community 3 comprised regulators of neuronal function that
were downregulated in SURF1 DNs (Fig. 4b, Supplementary
Data 4), including markers of neuronal morphogenesis and axon
guidance (ALCAM, CHL1, EFNB3, GAS7, RELN, SEMA3C,
SLIT2, SPON1), and markers of glial and neuronal development
(CDH6, CD44, GFAP, NCAM2, SYNPO) (Fig. 4c, d, Supplemen-
tary Fig. 4e). Downregulated proteomics-related pathways in
community 3 included cell compartments related to “cell
projection” and “synapse” (Supplementary Fig. 4g) and biological
processes regulating “neuron project guidance” (Supplementary
Fig. 4h). Decreased metabolites in SURF1 DNs included CNS-
specific metabolites such as N-acetyl aspartyl glutamate (NAG)
and N-acetyl aspartate (NAA), which is synthesized in mitochon-
dria and is known to be reduced in LS and neurological
disorders9,48 (Fig. 4e). Community 3 metabolites upregulated in
SURF1 DNs included folate and cAMP, which are important in
neuronal development and promotion of axonal growth49. The
increase of folate and cAMP, which were provided to DNs as part
of their medium, might suggest that they were not effectively
metabolized by mutant cells. Hence, impaired neuronal morpho-
genesis caused by SURF1 mutations may prevent the cells to
utilize the available neurodevelopmental-promoting cues.
Overall, multi-omics analysis of SURF1 neural cultures
suggested that metabolic defects caused by SURF1 mutations
constrained differentiating cells to retain a proliferative and
glycolytic state, which failed to support neuronal morphogenesis
and maturation.
LS-associated defects in metabolism, proliferation, and mor-
phogenesis emerge at the level of NPCs. We sought to validate
the occurrence of impaired neuronal morphogenesis in SURF1
cultures. We developed a high-content analysis (HCA) assay for
Fig. 3 Single-cell transcriptomics highlights an imbalance between proliferation and maturation in SURF1-mutant neural cultures and brain organoids.
a Uniform manifold approximation and projection (UMAP) plot showing the distribution of 4w DNs from CTL (CTL_NoMut: C1; SURF1_NoMut: S2_Corr1)
and SURF1 (SURF1_Mut: S2) (n= 2 independent experiments). b UMAP plot of 4w DNs from CTL (CTL_NoMut: C1; SURF1_NoMut: S2_Corr1) and SURF1
(SURF1_Mut: S2) showing seven cellular clusters (resolution= 1) (n= 2 independent experiments). c Dot plot highlighting the expression of representative
genes across clusters of DNs. Sizes of each dot reflect percentage of cells in the cluster where the gene is detected; colors reflect average expression level
within each cluster (yellow: low expression; red: high expression). d Cell cycle distribution in 4w DNs from CTL (CTL_NoMut: C1; SURF1_NoMut: S2_Corr1)
and SURF1 (SURF1_Mut: S2) (n= 2 independent experiments). e UMAP plot of 4w DNs from CTL (CTL_NoMut: C1; SURF1_NoMut: S2_Corr1) and SURF1
(SURF1_Mut: S2) showing cell cycle distribution (n= 2 independent experiments). f, g UMAP plots depicting signature distribution of cells expressing
proliferative genes TOΠ2A and MΨX in 4w DNs from CTL (CTL_NoMut: C1; SURF1_NoMut: S2_Corr1) and SURF1 (SURF1_Mut: S2) (n= 2 independent
experiments). h UMAP plot showing distribution of D90 organoids from CTL (SURF1_NoMut: S2_Corr1) and SURF1 (SURF1_Mut: S2) (3–8 organoids per
line per experiment, n= 2 independent experiments). i UMAP plot of D90 organoids from CTL (SURF1_NoMut: S2_Corr1) and SURF1 (SURF1_Mut: S2)
showing 13 cellular clusters (resolution= 0.6) (3–8 organoids per line per experiment, n= 2 independent experiments). j Dot plot expression of
representative genes across clusters of 90D organoids. k Cell cycle distribution in 90D organoids from CTL (SURF1_NoMut: S2_Corr1) and SURF1
(SURF1_Mut: S2) (3–8 organoids per line per experiment, n= 2 independent experiments). l UMAP plot of 90D organoids from CTL (SURF1_NoMut:
S2_Corr1) and SURF1 (SURF1_Mut: S2) showing cell cycle distribution (38 organoids per line per experiment, n= 2 independent experiments). m, n UMAP
plots depicting signature distribution of cells expressing proliferative genes TOΠ2A and MΨX in 90D organoids from CTL (SURF1_NoMut: S2_Corr1) and
SURF1 (SURF1_Mut: S2) (3–8 organoids per line per experiment, n= 2 independent experiments).
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quantitative assessment of neurite outgrowth and branching
complexity based on TUJ1-positive neuronal cells. We assessed
4w and 8w DNs from SURF1 (SURF1_Mut: S1, S2; CTL_Mut:
C1_Mut1) and CTL (CTL_NoMut: C1, C2, C3; SURF1_NoMut:
S2_Corr1, S2_Corr2). We used DNs derived from hESC line H1
as a baseline for CTL DNs.
SURF1 DNs at 4w and 8w exhibited significantly reduced
neurite length and number of branch points in comparison to
CTL DNs (Fig. 5a–c). Thus, SURF1 mutations impaired neuronal
morphogenesis not only in mature neurons (8w DNs) but also in
less mature neurons (4w DNs) (Fig. 5b, c). In fact, even if
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at 8w of neuronal differentiation, transcriptomic differences
between mutant and control DNs were already evident at 4w
(Supplementary Fig. 4c-d, Supplementary Data 9-10). These
results collectively indicated that disease defects might emerge
early during neurogenesis.
Next, we investigated whether iPSC-derived NPC cultures
(Supplementary Fig. 5a) would already exhibit disease pheno-
types. We had hints that SURF1 NPCs may be defective: 4w and
8w SURF1 DNs contained fewer NCAM-positive neuron-
restricted neural progenitors (Supplementary Fig. 5b), and the
SURF1-specific transcriptomic signature of SURF1 DNs and
SURF1 organoids was already, at least in part, recapitulated by
SURF1 NPCs (Supplementary Fig. 5c). We therefore compared
SURF1 NPCs (SURF1_Mut: S1, S2; CTL_Mut: C1_Mut1)
to CTL NPCs (CTL_NoMut: C1, C2, C3; SURF1_NoMut:
S2_Corr1, S2_Corr2). SURF1 NPCs exhibited mitochondrial
bioenergetic defects with reduced basal OCR, maximal respira-
tion, and ATP production compared to CTL NPCs (Fig. 5g, h,
Supplementary Fig. 5d). At the same time, SURF1 NPCs
retained a stronger glycolytic profile than CTL NPCs, with
higher extracellular acidification rate (ECAR) and increased
lactate release (Fig. 5i, j), which is a hallmark of LS4. The
findings are in accord with the upregulation of glycolysis in
SURF1 DNs suggested by multi-omics (Fig. 4c–e).
We addressed whether the metabolic defects of NPCs could be
recapitulated in non-neuronal cells. During the diagnostic work-
up, fibroblasts from SURF1 patients (SURF1_Mut: S1, S2) were
found to exhibit COX deficiency (see subject details in the
“Methods” section). However, when we measured the bioener-
getic profile of SURF1 fibroblasts (SURF1_Mut: S1, S2) compared
to control fibroblasts (CTL_NoMut: C2, C3), we did not detect
significant changes in their basal OCR or ATP production rate,
despite a slightly reduced maximal respiration rate (Fig. 5i,
Supplementary Fig. 5e). These results confirmed the known
tissue-specificity of SURF126,27, and suggest that the conse-
quences of COX deficiencies caused by SURF1 mutations may be
different in distinct cell types. Accordingly, SURF1 fibroblasts did
not show glycolytic upregulation; their ECAR levels were even
lower than those of control fibroblasts, and their lactate release
remained unchanged (Fig. 5j, k). We also failed to observe
significant changes in the mitochondrial or glycolytic profile of
undifferentiated SURF1 iPSCs (SURF1_Mut: S2) compared to
control iPSCs (CTL_NoMut: C1; SURF1_NoMut: S2_Corr1,
S2_Corr2) (Supplementary Fig. 5f-h). Altogether, SURF1 muta-
tions appeared to cause an impairment of energy metabolism that
affected neuronal cells more dramatically (Fig. 2c, d), and that
became evident already at the level of NPCs (Fig. 5d–h).
We next addressed the consequences of these metabolic defects
on NPC function. We compared SURF1 NPCs (SURF1_Mut: S1,
S2; CTL_Mut: C1_Mut1) to CTL NPCs (CTL_NoMut: C1, C2, C3;
SURF1_NoMut: S2_Corr1, S2_Corr2). SURF1 NPCs expressed
higher levels of proliferative and pluripotency-associated markers
(c-MYC, OCT4) (Fig. 5l, m). SURF1 NPCs also proliferated at
higher rates compared to CTL NPCs (Fig. 5n). NPCs thus
recapitulated the increase of proliferative and pluripotency-
associated markers and the cell cycle changes observed in SURF1
DNs (Fig. 3c–g, and 4c, d) and SURF1 organoids (Fig. 3j–n). SURF1
NPCs exhibited significantly elevated mtDNA copy numbers
(Fig. 5o), possibly as an attempt to compensate for the energy
deficiency by increasing the mitochondrial mass. Nonetheless, the
metabolic alterations of SURF1 NPCs did not affect the production
of mitochondrial reactive oxygen species (ROS) (Supplementary
Fig. 5i-j). Mitochondrial ROS in SURF1 NPCs remained similar to
those in CTL NPCs, both at the basal level and after mitochondrial
stress (Supplementary Fig. 5i, j). SURF1mutations also did not alter
the ultrastructural morphology of mitochondria in NPCs (Supple-
mentary Fig. 5k). Hence, the defective metabolism of NPCs did not
cause widespread mitochondrial alterations.
We next assessed the state of neuronal morphogenesis of
immature early neurons that are present within NPC cultures.
Although the branching length of these TUJ1-positive immature
neurons was small (Fig. 5p), we could detect significantly
decreased neurite outgrowth (neurite length and branching
points) in SURF1 NPCs compared to CTL NPCs (Fig. 5p–r).
We asked whether such neural morphogenesis defects could be
observed in other LS-causing mutations. We generated iPSCs
from two LS patients carrying mutations in the nuclear CI gene
NDUFS4 (Supplementary Fig. 5l). The first patient (NDU_1)
carried the mutation c.462delA p.(K154fs) and the second patient
(NDU_2) carried the mutation c.316C>T p.(R106*). We
compared NPCs derived from iPSCs carrying NDUFS4 mutations
(NDUFS4_Mut: NDU_1, NDU_2) to CTL NPCs (CTL_NoMut:
C1, C2, C3). NDUFS4 NPCs exhibited the expected reduction in
mitochondrial membrane potential (MMP) typical of CI
defects6,34 (Fig. 5s). TUJ1-positive neurons within NDUFS4
NPCs showed reduced neurite outgrowth compared to CTL
NPCs (Fig. 5t, u). These findings indicate that early neuronal
morphogenesis defects might potentially represent a general
pathogenetic mechanism of LS that is not restricted to SURF1
mutations.
Overall, SURF1 mutations prevented NPCs from shifting toward
OXPHOS, thereby promoting a proliferative and glycolytic state
associated with an insufficient lack of guidance clues to drive
neuronal morphogenesis.
Disrupted neuronal progenitor cytoarchitecture in SURF1-
mutant cerebral organoids. We aimed to address whether 3D
cerebral organoids (Supplementary Fig. 6a) could recapitulate
the disruption of NPC function and early morphogenesis
observed in 2D. We first carried out total RNA-sequencing of
D90 brain organoids from CTL (SURF1_NoMut: S2_Corr1) and
SURF1 (SURF1_Mut: S2) (Fig. 6a, Supplementary Data 11). The
expression pattern of genes belonging to the three communities
identified by xMWAS agreed with the results from the 2D
analysis (Fig. 6a, Supplementary Data 11). For genes in com-
munity 1, SURF1 organoids showed deregulated expression of
Fig. 4 Multi-omics analysis of SURF1 neural cultures identifies dysregulation of morphogens, metabolism/proliferation, and neuronal wiring.
a Schematics of multi-omics of 8w DNs from CTL (SURF1_NoMut: S2_Corr1) and SURF1 (SURF1_Mut: S2). b Multi-omics integration performed with
xMWAS identified three communities. Genes are indicated by squares, proteins by circles, and metabolites by triangles. c MA plot showing log fold
changes (LFC) of differentially expressed genes in 8w DNs from SURF1 (SURF1_Mut: S2) compared to CTL (SURF1_NoMut: S2_Corr1). Highlighted genes
are shown using colors of their respective community (n= 3 independent experiments). d Volcano plot depicting differentially expressed proteins in 8w
DNs from SURF1 (SURF1_Mut: S2) compared to CTL (SURF1_NoMut: S2_Corr1), after Benjamini–Hochberg correction for multiple testing. Highlighted
proteins are shown using colors of their respective community (n= 3 independent experiments). e Volcano plot depicting differentially detected
metabolites in 8w DNs from SURF1 (SURF1_Mut: S2) compared to CTL (SURF1_NoMut: S2_Corr1) after Benjamini–Hochberg correction for multiple testing
(n= 3 independent experiments). 2FDP: D-fructose 2,6-bisphosphate; 2PG: 2-phosphoglyceric acid; GSSG: oxidized-glutathione; GSH: reduced-
glutathione; NADP: nicotinamide adenine dinucleotide phosphate; NAA: N-acetyl aspartate; NAG: N-acetyl aspartyl glutamate.
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morphogens, including TGFβ (BMP4, TGFB2, IGF2BP1) and
WNT pathway (SFRP2, WNT2B) (Fig. 6a, Supplementary
Data 11). For genes in community 2, SURF1 organoids down-
regulated bioenergetic genes (PDK4, PPARGC1A) (Fig. 6a,
Supplementary Fig. 6b, Supplementary Data 11), and upregu-
lated glycolytic, proliferative, and pluripotency-associated genes
(MKI67, CENPE, CRABP2, MYC, LDHA, POU5F1) (Fig. 6a,
Supplementary Fig. 6b, Supplementary Data 11). Genes of
community 3 related to neuronal function were mainly down-
regulated in SURF1 organoids, including axon guidance genes
(CHL1, GAS7, RELN, SEMA3C, SLIT2), and glial and neuronal
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GFAP, LHX2) (Fig. 6a, Supplementary Fig. 6b, Supplementary
Data 11). These findings are in agreement with the observed
reduction of SYP-positive and synapsis 1 (SYN)-positive neu-
rons in SURF1 organoids compared to CTL organoids (Fig. 2i,
Supplementary Fig. 3n, Supplementary Fig. 6c).
We next investigated the state of neural progenitors within
brain organoids from SURF1 (SURF1_Mut: S1, S2; CTL_Mut:
C1_Mut1) and CTL (CTL_NoMut: C1, C2; SURF1_NoMut:
S2_Corr1). D40 CTL organoids contained LHX2-positive, SOX2-
positive, and PAX6-positive neural progenitor populations that
formed a well-organized architecture (Fig. 6b, Supplementary
Fig. 6d), and a tightly packed neuroepithelial layer reminiscent of
embryonic ventricles (Fig. 6c, white arrows). In contrast, D40
SURF1 organoids exhibited a disorganized neural progenitor
pattern of expression (Fig. 6b–c, Supplementary Fig. 6d), and a
disruption of neuroepithelial layers (Fig. 6c, white arrowhead).
The spatial organization of p-VIM-positive cells, indicating
dividing progenitors at subapical positions50, was lost in D40
SURF1 organoids (Fig. 6b). At D90, CTL organoids still exhibited
organized SOX2-positive progenitors, while this population was
almost undetectable in SURF1 organoids (Fig. 6c, Supplementary
Fig. 6e). The findings imply that increased progenitor prolifera-
tion might lead to the exhaustion of the NPC pool over time. In
agreement with lack of organized progenitor growth and
impaired neuronal differentiation, SURF1 organoids showed an
overall reduced size (Fig. 6d, Supplementary Fig. 6f). SURF1
organoids also exhibited impaired OXPHOS function, with a
decrease of OCR, maximal respiration, and ATP production rate
compared to CTL organoids (Fig. 6e–g).
Altogether, the aberrant cytoarchitecture of 3D brain organoids
confirmed the findings detected in 2D neural cultures, pointing
toward a dysregulation of NPC function and morphogenesis as a
mechanistic defect underlying SURF1-related pathogenesis.
Bezafibrate treatment and SURF1 gene augmentation enable
the metabolic shift of NPCs and restore early morphogenesis.
We reasoned that if the neuronal defects of LS stemmed from a
loss of NPC function, providing a healthy copy of the SURF1 gene
(without altering the presence of the mutation) could restore
neuronal morphogenesis by enhancing OXPHOS. We first used
lentiviruses to deliver wild-type (WT)-SURF1 to either SURF1
NPCs (SURF1_Mut: S1, S2) or 4w SURF1 DNs (SURF1_Mut: S1,
S2) (Supplementary Fig. 7a). WT-SURF1 improved the bioener-
getics of SURF1 NPCs (Fig. 7a and Supplementary Fig. 7b-c) and
the neuronal morphogenesis of SURF1 DNs (Fig. 7b, Supple-
mentary Fig. 7d). SURF1-WT also lowered the lactate production
of SURF1 DNs (Fig. 7c). We then used adeno-associated viruses
(AAV), which is a system currently considered for in vivo gene
transfer of CNS diseases51, to deliver WT-SURF1 to either SURF1
NPCs (SURF1_Mut: S1, S2) or 4w SURF1 DNs (SURF1_Mut: S1,
S2) (Supplementary Fig. 7e). Similar to lentiviruses, AAV delivery
of WT-SURF1 ameliorated the bioenergetics of SURF1 NPCs
(Fig. 7d, Supplementary Fig. 7f–h) and the morphogenesis of
SURF1 DNs (Fig. 7e–f). These results collectively suggest that it
may be possible to overcome SURF1 mutation-specific neuronal
defects with strategies that enhanced SURF1 function without
eliminating the causative mutations.
We then assessed the extent of recovery following therapeutic
strategies that have been proposed for LS. Hypoxia was beneficial
in animal models of LS caused by knock-out of the CI gene
Ndufs452,53. We exposed SURF1 NPCs (SURF1_Mut: S1, S2) to
hypoxia (5% oxygen) overnight (o.n.). Hypoxia improved
mitochondrial bioenergetics of SURF1 NPCs (Supplementary
Fig. 7i-k). However, hypoxia was not beneficial for NPC
morphogenesis, as it reduced neuronal outgrowth in CTL NPCs
and SURF1 NPCs (Supplementary Fig. 7l-m). The lack of
improvement on neuronal morphogenesis might be due to a
failure to support NPC to shift from glycolysis to OXPHOS. In
fact, hypoxia increased ECAR and lactate concentration in SURF1
NPCs (Supplementary Fig. 7n-o). We observed similar results in
SURF1 DNs (SURF1_Mut: S1, S2) exposed to o.n. hypoxia, which
showed higher lactate production and failed to improve neuronal
outgrowth (Supplementary Fig. 7p–r).
Next, we investigated the effects of antioxidants4,54. We treated
SURF1 NPCs (SURF1_Mut: S1, S2) o.n. with n-acetyl-cysteine
(NAC), alpha-tocotrienol (AT3), whose in vivo-derived metabolite
EPI-743 has been suggested as a therapy for LS55, ascorbic acid
(AA), and dihydrolipoic acid (DHLA). Although some antioxidants
lowered ECAR in SURF1 NPCs (Supplementary Fig. 7u), overall
antioxidants failed to improve mitochondrial bioenergetics and
morphogenesis of SURF1 NPCs (Supplementary Fig. 7t-v).
Metabolic manipulations including increasing doses of glucose or
pyruvate supplementation, previously proposed as treatment for LS
caused by COX defects56, also failed to promote OXPHOS and
neuronal morphogenesis in SURF1 NPCs (SURF1_Mut: S1, S2)
(Supplementary Fig. 7w–y).
Lastly, we investigated the potential benefits of pharmacologically
activating mitochondrial biogenesis in SURF1 neural cells. SURF1
DNs (SURF1_Mut: S1, S2) and SURF1 organoids (SURF1_Mut: S1,
S2) expressed reduced levels of PPARGC1A, which encodes for
the master regulators of mitochondrial biogenesis PGC1A57
(Supplementary Fig. 4f, Supplementary Fig. 6b). We confirmed
Fig. 5 LS-associated defects in neuronal morphogenesis emerge at the level of NPCs. a–c HCA masks and neuronal morphogenesis of 4w and 8w
DNs from CTL (CTL_NoMut: C1, C2, C3; SURF1_NoMut: S2_Corr1) and SURF1 (SURF1_Mut: S1, S2: CTL_Mut: C1_Mut1) (mean ± s.e.m.; n= 20 biological
replicates (dots) per line over three independent experiments; ****p < 0.0001 CTL vs. SURF1; two-sided Mann–Whitney U test). Scale bar: 50 µm.
d–h Bioenergetic profile and lactate release in NPCs from CTL (CTL_NoMut: C1, C2, C3; SURF1_NoMut: S2_Corr1) and SURF1 (SURF1_Mut: S1, S2;
CTL_Mut: C1_Mut1) (mean ± s.e.m.; n= 20 biological replicates (dots) per line over three independent experiments; ***p < 0.001, ****p < 0.0001 CTL vs.
SURF1; two-sided Mann–Whitney U test). i–k Bioenergetic profile and lactate release in fibroblasts from CTL (CTL_NoMut: C2, C3) and SURF1
(SURF1_Mut: S1, S2) (mean ± s.e.m.; n= 15 biological replicates (dots) per line (i, j) and n= 4 biological replicates (dots) per line (k) over two independent
experiments; n.s.= not significant, **p < 0.01 CTL vs. SURF1; two-sided Mann–Whitney U test). l, m QRT-PCR in NPCs from CTL (CTL_NoMut: C1, C2, C3;
SURF1_NoMut: S2_Corr1) and SURF1 (SURF1_Mut: S1, S2; CTL_Mut: C1_Mut1) (normalized to AXTB; mean ± s.e.m.; n= 10 replicates per line over two
independent experiments; ****p < 0.0001 CTL vs. SURF1; two-sided Mann–Whitney U test). n, o 24 h proliferation and mtDNA quantification (normalized
over genomic DNA, gDNA) in NPCs from CTL (CTL_NoMut: C1, C2, C3; SURF1_NoMut: S2_Corr1) and SURF1 (SURF1_Mut: S1, S2; CTL_Mut: C1_Mut1)
(mean ± s.e.m.; n= 20 biological replicates (dots) per line (n) and n= 4 biological replicates (dots) per line (o) over three independent experiments;
****p < 0.0001 CTL vs. SURF1; two-sided Mann–Whitney U test). p–r HCA masks and neuronal morphogenesis in NPCs from CTL (CTL_NoMut: C1, C2, C3;
SURF1_NoMut: S2_Corr1) and SURF1 (SURF1_Mut: S1, S2) (mean ± s.e.m.; n= 20 biological replicates (dots) per line over three independent experiments;
****p < 0.0001 CTL vs. SURF1; two-sided Mann–Whitney U test). Scale bar: 50 µm. s–u Mitochondrial membrane potential (MMP) quantification and
morphogenesis in NPCs from CTL (CTL_NoMut: C2, C3) and NDUFS4 (NDUFS4_Mut: NDU_1, NDU_2) (mean ± s.e.m.; n= 4 biological replicates (dots)
per line over three independent experiments; ****p < 0.0001 CTL vs. NDUFS4; two-sided Mann–Whitney U test).
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that PGC1A protein levels were low in SURF1 NPCs (SURF1_Mut:
S1, S2; CTL_Mut: C1_Mut1) compared to CTL NPCs (CTL_No-
Mut: C1, C2; SURF1_NoMut: S2_Corr1) (Fig. 7g, h). To activate
PGC1A in SURF1 NPCs (SURF1_Mut: S1, S2; CTL_Mut:
C1_Mut1), we first used the peroxisome proliferator-activated
receptor (PPAR) agonist bezafibrate (BZ), which has been suggested
for the treatment of neurological and mitochondrial disorders58,59.
Treatment of SURF1 NPCs with 400 µM BZ o.n. increased PGC1A
protein content (Fig. 7g, i) and elevated mtDNA copy number
(Fig. 7j). BZ treatment in SURF1 NPCs also lowered the expression
of proliferative and pluripotency-associated markers (c-MYC,
OCT4) (Fig. 7k, l), and reduced cellular proliferation (Fig. 7m).
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Increasing doses of BZ treatment enhanced OXPHOS metabolism
in SURF1 NPCs (Fig. 7n–p), and reduced glycolytic metabolism
(Fig. 7q). Consequently, BZ improved the morphogenesis of SURF1
NPCs (Fig. 7r, Supplementary Fig. 7s). Lentivirus-mediated over-
expression of PGC1A in SURF1 NPCs (SURF1_Mut: S1, S2;
CTL_Mut: C1_Mut1) also improved OXPHOS bioenergetics and
neuronal morphogenesis (Fig. 7s, t). These latter results confirmed
that increased PGC1A expression might be the mechanism
responsible for the beneficial effect of BZ treatment on
SURF1 NPCs.
In summary, the loss of NPC function caused by SURF1
mutations could be overcome (i) through viral-based gene
augmentation of WT-SURF1 or (ii) through the increase of
mitochondrial biogenesis via PGC1A induction that can be
elicited by bezafibrate treatment (Supplementary Fig. 8). These
two strategies enabled NPCs to shift toward oxidative metabolism
and thereby supported neuronal morphogenesis.
Discussion
SURF1 mutations are among the most frequent monogenic
defects causing LS, an incurable mitochondrial disease in children
for which we lack a mechanistic understanding due to the paucity
of effective model systems6. We discovered that SURF1 mutations
cause human neuronal impairment as a result of defective
metabolic programming of NPCs that prevents the establishment
of neuronal morphogenesis.
During neurogenesis, there is a shift from glycolysis to oxida-
tive mitochondrial metabolism60–62. NPCs may represent the first
cell type in this process to depend on OXPHOS function31,63,64.
For this reason, OXPHOS-related defects might already emerge at
the level of NPCs. Due to respiratory defects caused by SURF1
mutations, SURF1 NPCs failed to undergo the metabolic shift,
and retained glycolytic and proliferative features, which in turn
hampered the establishment of neuronal morphogenesis. SURF1
mutations did not lead to redox damage or widespread alterations
of mitochondrial morphology, but caused metabolic defects that
were rather specific to neuronal lineage cells. iPSCs and fibro-
blasts carrying the same SURF1 mutations did not show the
dramatic phenotypes observed in neural cells. Patient fibroblasts
had isolated COX deficiency, but did not respond to this primary
defect with a strong reduction of mitochondrial bioenergetics and
upregulation of glycolysis. Perhaps this phenomenon is related to
the known species-specific and tissue-specific effects of SURF1 on
the assembly of COX26,27. In fact, COX has been suggested to
contribute to the establishment of the transcriptional neuronal
network65 and to possibly represent an endogenous metabolic
marker for neuronal activity65,66. Hence, improper COX assem-
bly might lead to more dramatic consequences in neural cells.
In 3D cultures, dysfunctional NPCs disrupted the physiological
neuronal layering causing aberrant cytoarchitecture. At later
time points, brain organoids exhibited NPC exhaustion with
impaired neuronal generation and reduced overall organoid size.
Mitochondrial bioenergetics is crucial for axonal arborization and
synaptic function67,68. Neuronal wiring is crucial during brain
development69. A failure to establish the orchestrated develop-
mental events responsible for proper neuronal wiring and gui-
dance can affect synaptogenesis and neuronal circuit formation70.
These defects could underpin the cognitive and developmental
impairment of LS patients and their susceptibility to metabolic
disturbances that ultimately lead to neuronal cell dysfunction and
death71.
The genetic causes of LS are quite heterogeneous5, but key
pathological features are relatively conserved40. Therefore, the
mechanisms identified for SURF1 mutations might be potentially
representative of general LS pathogenesis. Accordingly, we con-
firmed the presence of defective neurite outgrowth also in NPCs
carrying mutations in the CI gene NDUFS4, another well-known
cause of LS34. Previous studies demonstrated that NPCs carrying
other LS-associated mutations showed bioenergetic defects28 and
mitochondrial calcium dyshomeostasis29,31. Hence, NPCs may play
an unexpected role in the pathophysiology of LS. Since NPCs are
not specific to the dopaminergic lineage, it is possible that several
neuronal subtypes may be affected in LS. Accordingly, cerebral
organoids from LS patients carryingMT-ATP6 mutations displayed
impaired maturation of cortical neurons, leading to an overall
reduction of organoid size32. This is in agreement with the
decreased organoid size that we observed for SURF1mutations. It is
interesting to point out that, in addition to developmental delay9,
microcephaly is often present in LS patients72. Collectively, the
findings suggest that LS might occur more frequently than reported;
the defects in early neuronal morphogenesis may prevent the
normal course of brain development in some cases, leading to early
termination of pregnancy.
Our study highlights two potential intervention strategies for
LS caused by SURF1 mutations, namely gene augmentation
therapy (GAT) and bezafibrate treatment (Supplementary Fig. 8).
There are currently no FDA-approved drugs for mitochondrial
disease18,19,54. Using a GAT approach, we found that SURF1
mutations caused a loss of function that could be overcome by
expressing a healthy copy of SURF1 without eliminating the
diseased gene. AAV-based GAT is currently considered for var-
ious monogenic diseases of the nervous system51. Recently, the
FDA-approved AAV-based GAT to treat children with spinal
muscular atrophy73. In the context of LS, AAV-based GAT
ameliorated the disease phenotypes in Ndufs4 knock-out
mice74,75. Further studies of SURF1 GAT in living animals are
needed to identify potential side effects and improve delivery
strategies.
By investigating the disease pathophysiology, we found that
SURF1 NPCs exhibited reduced levels of PGC1A, a master reg-
ulator of mitochondrial biogenesis57. Increasing mitochondrial
biogenesis in SURF1 NPCs via PGC1A overexpression or via
bezafibrate treatment promoted the OXPHOS shift and sup-
ported neuronal morphogenesis. Accordingly, elevating mtDNA
Fig. 6 Aberrant cytoarchitecture and neural progenitor organization in SURF1 brain organoids. a MA plot showing LFC of differentially expressed genes
in D90 brain organoids from CTL (SURF1_NoMut: S2_Corr1) and SURF1 (SURF1_Mut: S2) (3–8 organoids per line per experiment, n= 3 independent
experiments). Highlighted genes in community colors (orange: signaling and morphogens; blue: metabolism and cell cycle; green: axon guidance and
synapsis). b, c Cerebral organoids from CTL (SURF1_NoMut: S2_Corr1) and SURF1 (SURF1_Mut: S2) at D40 and D90. White arrows indicate SOX2-positive
neuroepithelium surrounding embryonic-like ventricles; white arrowhead indicates abnormal structure of neuroepithelium layering. Reproduced in CTL
(CTL_NoMut: C1, C2) and SURF1 (SURF1_Mut: S1; CTL_Mut: C1_Mut1) (3–8 organoids per line per experiment, n= 3 independent experiments). Scale bar:
100 µm. d Representative images and quantification of the size of D90 organoids from CTL (CTL_NoMut: C1, C2; SURF1_NoMut: S2_Corr1) and SURF1
(SURF1_Mut: S2; CTL_Mut: C1_Mut1) (mean ± s.e.m.; 20–30 organoids measured per line per experiment; n= 5 independent experiments; ****p < 0.0001
CTL vs. SURF1; two-sided Mann–Whitney U test). e–g Bioenergetic profile of D40 organoids from (CTL_NoMut: C1, C2; SURF1_NoMut: S2_Corr1) and
SURF1 (SURF1_Mut: S2, C1_Mut1; CTL_Mut: C1_Mut1) (mean ± s.e.m.; 5–15 organoids per line per experiment; n= 2 independent experiments; ****p <
0.0001 CTL vs. SURF1; two-sided Mann–Whitney U test).
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copies was beneficial in mice with pathogenic mtDNA
mutations76, and overexpression of PGC1A in Surf1 knock-out
mice improved OXPHOS activity77. Bezafibrate treatment has
been suggested for treating neurological diseases58,78. Although
bezafibrate did not improve mitochondrial function in Surf1
knock-out mice77, it was effective in delaying the accumulation of
mtDNA deletions in mice79. A recent open-label study demon-
strated the functional benefit of bezafibrate in six patients with
mitochondrial cardiomyopathy59. The study also found an
increase in serum growth factors that are associated with mito-
chondrial diseases, suggesting that long-term studies are needed
to explore the risks and benefits of bezafibrate treatment.
Interestingly, patient S1, from whom we derived the iPSCs used
in this study, was treated with bezafibrate for nine years. He
beneficially responded to the treatment with improved respiratory
function, reduction of dystonic episodes, and fewer metabolic
crises. Possibly because of this treatment, patient S1 reached 25
years of age, which is among the oldest age reported for LS
patients carrying SURF1 mutations.
We addressed the effect of hypoxia in LS human neural cells.
Hypoxia was beneficial in animal models of LS based on Ndufs4
knock-out52,53. However, hypoxia exposure in SURF1 NPCs
increased glycolysis and failed to promote the switch to OXPHOS
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or pyruvate supplementation that has been suggested as a therapy
for LS56 also failed to boost OXPHOS in SURF1 NPCs. Further
studies investigating additional metabolic manipulations and
exploring the long-term consequences of hypoxia and its effects
on 3D architecture should be undertaken to clarify these issues.
Our model does not provide support for the use of anti-
oxidants to treat LS. It is interesting to point out that the
current understanding of LS is that the disease is caused by
neuronal degeneration. This interpretation had led to experi-
mental treatment schemes centered on antioxidants to prevent
the build-up of damaging free radicals4. However, these treat-
ments did not show the expected positive outcomes18,19,54.
In fact, antioxidant regiments may dampen the physiological
effect of free radical signaling, thereby blunting compensatory
responses80. Antioxidants were also found to exacerbate the
susceptibility to cell death in fibroblasts from patients affected
by French Canadian variant of Leigh syndrome81. Our findings
provide a novel perspective to LS pathology by showing that the
disease mechanisms may not necessarily involve a redox
imbalance but rather an impairment of neuronal morphogen-
esis following the loss of NPC commitment.
Taken together, our data underscore the importance of meta-
bolic programming—and particularly the metabolic shift toward
OXPHOS at the level of neural progenitors—for physiological
human neurogenesis, and are in agreement with recent studies
demonstrating that mitochondrial metabolism is instructive for
neurogenesis82. These findings may also help explain the presence
of intellectual disability in patients with mitochondrial diseases.
Our work sheds new light on the mechanisms underlying the
neuronal pathology of mitochondrial disease in children and
suggests implementable interventions against LS, a rare incurable
pediatric disease with significant unmet medical needs.
Methods
Subject details. We obtained written informed consent to use patient material
from the guardians according to the Declaration of Helsinki. The study was
approved by the IRB of the Charité (ethical approval EA2/131/13 and EA2/107/14).
We obtained skin fibroblasts from two patients (S1 and S2) belonging to two
distinct consanguineous families. Patient S1 was male with healthy parents, who
were first-degree cousins from Turkey. His disease manifested with a pronounced
action tremor, progressive ataxia, and episodes of hyperventilation at the age of 2
years. Cranial MRI uncovered bilateral basal ganglia necroses and T2-signal
intensities in the brainstem at the formatio reticularis (Supplementary Fig. 1a). CSF
lactate was elevated to 4.3 mmol/l (normal: <2). Muscle and skin biopsy at 2 years
of age revealed low COX activity in muscles (15 mU/mg NCP; normal: 90–281)
and in cultured skin fibroblasts (130 mU/U CS; normal: 680–1190), while the other
respiratory chain complexes were normal. Sequencing of SURF1 (NM_003172)
showed a homozygous variant c.530T > G p.(V177G) in exon 6 that was hetero-
zygous in both parents. Segregation of the mutation was verified by primer-induced
restriction analysis (PIRA) (Supplementary Fig. 1b). From the age of 6 months his
growth fell below the third percentile. At 18 years of age, his height was 45 cm
below and his head circumference 8 cm below the third percentile. Seizures were
treated successfully with Levetiracetam. From the age of 15 years, frequent meta-
bolic crises with respiratory insufficiency required intermittent mechanical venti-
lation at home through a tracheostoma. His overall clinical situation considerably
improved under therapy with the PPAR-agonist bezafibrate (8 mg/kg BW). The
patient died at the age of 25 years from a pulmonary bacterial infection and sepsis.
Patient S2 was a male from healthy consanguineous parents from Turkey. He was
born with hypospadia grade II and was very hirsute from birth. Muscle weakness
became evident around 2 years of age. Cranial MRI revealed the characteristic basal
ganglia necrosis of LS (Supplementary Fig. 1c). At 20 months of age, biochemical
investigation confirmed COX deficiency in muscle (158 mU/U CS; normal:
5202080) and in cultured fibroblasts (100 mU/U CS; normal: 342–627). Other
OXPHOS complex activities were normal. Sequence analysis of SURF1
(NM_003172) detected a homozygous c.769G>A p.(G180R) variant in exon 8.
Segregation of the mutation in the family was verified by PIRA (Supplementary
Fig. 1d). By the age of 3.5 years, he had lost muscle force and the ability to walk, sit,
and speak. Triggered by a febrile Mycoplasma pneumoniae infection, he developed
choreiform movements and lactate levels rose to 4.5 mmol/l (normal: <2). The
patient died from global respiratory and cardiac failure at 5 years of age.
Skin fibroblasts from two patients with NDUFS4 mutations (NM_002495.2)
were derived at Salzburg Medical University. We obtained written informed
consent to use patient material from the guardians according to the Declaration of
Helsinki. The study was approved by Technical University Muenchen (ethical
approval 5360/12S). Patient NDU_1 was 5-month-old male carrying the mutation
c.462delA p.(K154fs) and died at 6 months of age. Patient NDU_2 was a 4 months-
old female carrying the mutation c.316C > T p.(R106*); she died at 7 months of age
and was previously described as P134.
All information regarding patient details is reported in Supplementary Data 13.
Derivation and cultivation of iPSCs. We reprogrammed skin fibroblasts obtained
from the two SURF1 patients (S1 and S2) and two NDUFS4 patients (NDU_1 and
NDU_2) using Sendai viruses (CytoTune-iPS 2.0 #A16517, Thermo Fisher Sci-
entific, Waltham, MA, USA). Control iPSC lines were all previously generated. Dr.
Heiko Lickert (Helmholtz Center Munich) kindly provided the CTL iPSC line C1,
which was previously named XM001 and was generated using episomal plasmids83.
The MDC Stem Cell Core facility kindly provided the CTL iPSC line C2, which was
generated by SCVI Stanford Cardiovascular Institute using Sendai viruses and was
originally named SCVI113. We previously generated the CTL iPSC line C3, which
we derived using episomal plasmids and named TFBJ31. We purchased the human
embryonic stem cell (hESC) line H184 from WiCell, and we used it in accordance
with the German license issued to Dr. Alessandro Prigione by the Robert Koch
Institute (AZ: 3.04.02/0077). We cultured all iPSCs and hESCs on Matrigel
(Corning Inc., Corning, NY, USA, #734-1100)-coated plates using StemMACS iPS-
Brew XF medium (Miltenyi Biotec, Bergisch Gladbach, Germany, #130-104368),
supplemented with Pen/Strep (Thermo Fisher Scientific, Waltham, MA, USA,
#15140122) and MycoZap (Lonza, Basel, Switzerland, #LT017-918). We routinely
monitored against mycoplasma contamination using PCR. We added 10 µM
ROCK inhibitor (Enzo Biochem Inc., Farmingdale, NY, USA, #ALX-270-333-
M005) after splitting to promote survival. We kept PSC cultures in a humidified
atmosphere of 5% CO2 at 37 °C and atmospheric oxygen. Karyotype analysis was
performed by MDC Stem Cell Core Facility. Briefly, DNA was isolated using the
Fig. 7 SURF1 gene augmentation and bezafibrate treatment ameliorate bioenergetics and morphogenesis in patient neural cells. a Bioenergetics of
NPCs (SURF1_Mut: S1, S2) with mCitrine or WT-SURF1 (mean ± s.e.m.; n= 20 biological replicates (dots) per line over three independent experiments;
***p < 0.001; two-sided Mann–Whitney U test). b, c Morphogenesis and lactate in 4w DNs (SURF1_Mut: S1, S2) with mCitrine or WT-SURF1 (mean ± s.e.
m.; n= 3 biological replicates (dots) per line over three independent experiments; **p= 0.0022, ****p < 0.001; two-sided Mann–Whitney U test).
d Bioenergetics of NPCs (SURF1_Mut: S1, S2) with mCitrine or WT-SURF1 (mean ± s.e.m.; n= 5 biological replicates (dots) per line over two independent
experiments; ****p < 0.0001; two-sided Mann–Whitney U test). e, fMorphogenesis of 4w DNs (SURF1_Mut: S1, S2) with mCitrine or WT-SURF1 (mean ± s.
e.m.; n= 10 biological replicates (dots) per line over two independent experiments; *p= 0.0174, **p= 0.0061; two-sided Mann–Whitney U test).
g–i PGC1A immunoblot and densitometry of NPCs from CTL (CTL_NoMut: C1, C2; SURF1_NoMut: S2_Corr2) and SURF1 (SURF1_Mut: S1, S2; CTL_Mut:
C1_Mut1) UT or with 400 µM BZ (mean ± s.e.m.; n= 2 independent experiments; *p < 0.05 SURF1-UT vs. CTL-UT, n.s not significant CTL BZ vs. CTL-UT;
**p < 0.01 SURF1 BZ vs. SURF1-UT; two-sided Mann–Whitney U test). j mtDNA quantification in NPCs from CTL (CTL_NoMut: C1, C2, C3; SURF1_NoMut:
S2_Corr1) and SURF1 (SURF1_Mut: S2; CTL_Mut: C1_Mut1) UT or with 400 µM BZ (mean ± s.e.m.; n= 5 biological replicates (dots) per line over two
independent experiments; n.s.= not significant CTL BZ vs. CTL-UT; *p < 0.05 SURF1 BZ vs. SURF1-UT; two-sided Mann–Whitney U test). k–m QRT-PCR
(normalized to AXTB) and 24 h proliferation in NPCs (SURF1_Mut: S1, S2; CTL_Mut: C1_Mut1) UT or with BZ (mean ± s.e.m.; n= 10 replicates (dots) per
line over two independent experiments; *p < 0.05, ****p < 0.0001; two-sided Mann–Whitney U test). n–r Bioenergetics and morphogenesis of NPCs
(SURF1_Mut: S1, S2; CTL_Mut: C1_Mut1) UT or with BZ (mean ± s.e.m.; n= 15 biological replicates (dots) over three independent experiments; *p= 0.038,
**p= 0.0069, ****p < 0.0001; two-sided Mann–Whitney U test). s, t Bioenergetics and morphogenesis of NPCs (SURF1_Mut: S1, S2; CTL_Mut: C1_Mut1)
with mCitrine or PGC1A (mean ± s.e.m.; n= 10 biological replicates (dots) per line over two independent experiments; *p < 0.05; two-sided Mann–Whitney
U test). Horizontal blue lines in all panels: average values CTL (CTL_NoMut: C1; SURF1_NoMut: S2_Corr1).
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DNeasy blood and tissue kit (Qiagen, Venlo, Netherlands, #69504). SNP kar-
yotyping was assessed using the Infinium OmniExpressExome-8 Kit (Illumina, San
Diego, CA, USA, #200224676) and the iScan system from Illumina (Illumina, San
Diego, CA, USA). CNV and SNP visualization was performed using KaryoStudio
v1.4 (Illumina, San Diego, CA, USA). In Supplementary Data 13, we report all the
details related to control lines, patient lines, and genome-edited lines, and their use
across experiments.
CRISPR/eCas9 genome editing. We prepared sgRNA-Cas9 plasmids for the
generation of isogenic corrected iPSC lines SURF1_NoMut (S2_Corr1, S2_Corr2,
S2_Corr3) and isogenic mutant iPSC lines CTL_NoMut (C1_Mut1, C1_Mut2)
following our published protocol85. To target the SURF1 c.769G>A mutation, we
designed two sgRNAs oligo pairs targeting A>G and G>A variants using CRISPOR
(http://crispor.tefor.net/) based on hg38 reference (GRCh, Genome Reference
Consortium Human Reference38) with manual modification of G>A in sgRNA
targeting the mutated SURF1 variant in S2 line. We cloned sgRNAs oligo pairs into
sgRNA-Cas9 plasmid (Addgene #86986, Watertown, MA, USA) carrying enhanced
specificity (eSpCas9) variant of SpCas9 with reduced off-target effects and robust
on-target cleavage obtained from the eSpCas9(1.1) plasmid (Addgene, Watertown,
MA, #71814)36. For editing by generation of double-strand breaks (DSBs) 8 nt
upstream of the region of interest and repair of the DNA cleavage using single-
stranded template repair pathway (SSTR) with single-stranded DNA, we designed
149 nt single-strand oligo-deoxynucleotide (ssODN) templates carrying A>G
(correction) and/or G>A (introduction) variants and two silent mutations within
sgRNAs binding region in close proximity to the protospacer adjacent motif
(PAM) site (3 and 6 nt downstream) to prevent the templates from recurrent eCas9
cleavage in edited cells. In order to improve the DNA recombination after eCas9-
induced DSBs cleavage by SSTR and ssODNs, we applied ectopic expression of
human RAD52 (for SSTR upregulation) and dominant-negative sub-fragment of
murine 53BP1 (dn53BP1), which may counteract the endogenous 53BP1 (for non-
homologous end-joining - NHEJ downregulation)37. Components of the two DNA
repair pathways (RAD52, dn53BP1) were kindly provided by Dr. Bruna S. Paulsen
(Harvard University, Cambridge, MA, USA). We generated RAD52 and dn53BP1
expression plasmids by sub-cloning of the RAD52 and dn53BP1 PCR products into
CAG expression plasmid. We carried out transient transfection of corresponding
plasmids and SSTR templates in S2 and C1 lines grown in feeder-free conditions in
StemMACSTM iPS-Brew XF, human culture media (Miltenyi Biotec, Bergisch
Gladbach, Germany, #130-104-368) in a 6-well culture plate. One day before
transfection, we dissociated the cells using Stem Pro Accutase (Thermo Fisher
Scientific, Waltham, MA, USA, #A1110501) and seeded ~1 × 105 cells per well of a
Matrigel-coated 6-well plate as single cells or small clumps. We cultivated the cells
in fresh medium containing 10 µM ROCK inhibitor overnight. We performed
lipofection using the Lipofectamine 3000 Kit (Thermo Fisher Scientific, Waltham,
MA, USA, #L3000015), according to the manufacturer’s protocol. We diluted the
plasmids to 2 mg DNA in 125 ml of Opti-MEM reduced serum medium (Gibco/
Thermo Fisher Scientific, Waltham, MA, USA, #31985062) and added the DNA-
lipid complex to one well of a 6-well plate in a dropwise manner with the addition
of 5 µM ROCK inhibitor to the culture medium for 24 h. We changed the medium
on the following day, and then kept the cells in culture until fluorescence-activated
cell sorting (FACS). We next dissociated the cells using Accutase for 5 min, washed
them with PBS, and resuspended them in DPBS. We filtered the cells using Falcon
polystyrene test tubes (Corning, NY, USA, #352235) and transferred them to
Falcon polypropylene test tubes (Corning, NY, USA, #352063). We performed
FACS-based cell sorting using BD FACSAria III at the MDC FACS Facility. We
resuspended the sorted cells in recovery mTeSRTM medium (STEMCELL Tech-
nologies, Vancouver, Canada, #85850) with 1X Penicillin-Streptomycin (P/S) and
ROCK inhibitor and plated them onto Matrigel-coated 6-well plates (5 K cells/
well). We transferred the growing single-cell-derived from 6-well plates to one well
each of 24-well plate and maintained them until the colony grew large enough to be
partially harvested for DNA isolation using Phire Animal Tissue Direct PCR Kit
(Thermo Fisher Scientific, Waltham, MA, USA, #F140WH). We carried out PCR
reactions using 100 ng gDNA in 50 ml with Phusion High-Fidelity DNA Taq
polymerase (Thermo Fisher Scientific, Waltham, MA, USA, #F530L) according to
manufacturer’s instructions and annealing temperature of 61 ˚C. For Sanger
sequencing or fragment analysis, we gel-purified the PCR products using the
Wizard SV Gel and PCR Clean-Up System (Promega, Madison, WI, USA,
#A9281). We amplified SURF1 gene product with S2 primers (product length
550 nt). For primer-induced restriction analysis (PIRA) the PCR product of 550 nt
was cut by BbsI (NEB, Ipswich, MA, USA, #R3539) into 221+ 324 nt fragments
only in the presence of the mutation c.769G>A. We submitted PCR products to
LGC (https://www.lgcgroup.com, Teddington, UK) for Sanger sequencing.
Primers, sgRNA, and HDR templates sequences are reported in supplementary
Supplementary Data 12.
Whole-genome sequencing (WGS) and off-target effects analysis. We isolated
genomic DNA (gDNA) from iPSCs SURF1_Mut (S2) and SURF1_NoMut
(S2_Corr1) using FlexiGene DNA isolation kit (Qiagen, Venlo, Netherlands, #51206).
WGS was performed by BGI using standard procedures. In accordance with the
German privacy protection laws, we are not allowed to deposit the genomic datasets
on open repositories. For analysis of off-target effects of CRISPR/eCas9 genome
editing, we used the CrispRGold 1.1 algorithm (https://crisprgold.mdc-berlin.de,
MDC, Berlin, Germany) for rigorous prediction of off-target sites based on applied,
and manually modified (G >A) sgRNA. We next interrogated the WGS datasets of
S2_Corr1 to identify potential mismatches compared to the parental line S2. The
results of the analyzed top-ranked 58 sites are reported in Supplementary Data 1.
Generation of neural progenitor cells (NPCs) and differentiated neuronal
cultures (DNs). We obtained NPCs and DNs using a previously published
protocol39. Briefly, we detached PSCs from Matrigel-coated plates using Accutase
(1 mg/ml) and transferred the collected cells into low-attachment Petri dishes
where they were kept for 2 days in Neurobasal:DMEM/F12 [1:1] (Gibco/Life
Technologies, Thermo Fisher Scientific, Waltham, MA, USA, #21103049),
N2 supplement [1x] (Gibco/Life Technologies, Waltham, MA, USA, #17502048),
B27 supplement without vitamin A [1x] (Gibco/Life Technologies, Thermo Fisher
Scientific, Waltham, MA, USA, #12587010) with the addition of Purmorphamine
(PMA) [0.5 µM] (Merck Millipore, Burlington, MA, USA, #483367), CHIR 99021
[3 µM] (Cayman Chemical, Ann Arbor, MI, USA, #13122), SB-431542 [10 µM]
(Selleckchem, Houston, TX, USA, #S1067). From day 2 to day 6, the media was
switched to: Neurobasal:DMEM/F12 [1:1], N2 [1x], B27 without vitamin A [1x]
with the addition of PMA [0.5 µM], CHIR 99021 [3 µM], ascorbic acid [150 µM]
(all from Sigma-Aldrich, St. Louis, MO, USA, #A92902). On day 6, we transferred
the suspended cells onto Matrigel-coated well plates using: Neurobasal:DMEM/F12
[1:1], N2 [1x], B27 without vitamin A [1x]. We maintained NPCs on this media
without ROCK inhibitor and used them for experiments between passage 7 and
passage 20. For DNs, we used NPCs between passage 7 and passage 13. To initiate
the differentiation, we switched the media to: Neurobasal:DMEM/F12 [1:1], N2
[1x], B27 with vitamin A [1x] (Gibco/Life Technologies, Thermo Fisher Scientific,
Waltham, MA, USA, #17504-044) with the addition of ascorbic acid [100 µM],
FGF8 [100 ng/ml] (R&D Systems, Minneapolis, MN, USA, #4745-F8-050), PMA
[0.5 µM]. After 7 days, we replaced the media condition with: Neurobasal:DMEM/
F12 [1:1], N2 [1x], B27 with vitamin A [1x] with the addition of ascorbic acid [100
µM], FGF8 [100 ng/ml], PMA [0.25 µM]. On day 9, we split the cells with Accutase
and seeded on Matrigel-coated plates in Neurobasal:DMEM/F12 [1:1], N2 [1x],
B27 with vitamin A [1x], with the addition of ascorbic acid [200 µM], cAMP
[500 µM] (Sigma-Aldrich, St. Louis, MO, USA, #D0627), BDNF [10 ng/ml] (Mil-
tenyi Biotec, Bergisch Gladbach, Germany, #130-093-811), GDNF [10 ng/ml]
(Miltenyi Biotec, Bergisch Gladbach, Germany, #130-096-291), and TGFbeta3
[1 ng/ml] (Miltenyi Biotec, Bergisch Gladbach, Germany, #130-094-007). We
added 10 µM ROCK inhibitor after each splitting to promote survival. We changed
the media every 3–4 days, and then kept the differentiated cells in culture for 4, 6,
and 8 weeks to reach different maturation stages. We performed magnetic-
activated cell sorting (MACs) to quantify NCAM-positive cells using PSA-NCAM-
PE antibody (Miltenyi Biotec, Bergisch Gladbach, Germany, #130-093-274),
according to the manufacturer’s instructions. For cytokine quantification in the
culture media of DNs derived from H1, C1, S1, and S2. We collected the super-
natants, concentrated them with Amicon 10 K (Merk Millipore Burlington, MA,
USA, #C78144), and analyzed them using the Pro-inflammatory Panel I (MesoS-
cale Discovery, Gaithersburg, MD, USA) using an electrochemiluminescent
detection method. We performed all experiments with NPCs and DNs using cells
grown in glucose-containing medium.
Generation of cerebral organoids. We generated iPSC-derived cerebral organoids
according to a protocol previously described with some modifications41,42. Shortly,
after dissociation into single-cell suspension with Accutase, we seeded 5000–10,000
cells per one well of 96-well plates in 100 µl of embryoid body (EB) medium
containing: DMEM/F12, KnockOutTM Serum Replacement (Thermo Fisher Sci-
entific, Waltham, MA, USA, #10828-028), GlutaMAXTM Supplement (Thermo
Fisher Scientific, Waltham, MA, USA, #35050061), MEM-NEAA (Gibco/Thermo
Fisher Scientific, Waltham, MA, USA, #11140035), ESC FBS (Thermo Fisher Sci-
entific, Waltham, MA, USA, #16141079), bFGF (PeproTech, Rocky Hill, NJ, USA,
#100-18B), and 50 µM ROCK inhibitor. After 4 days, we replaced the medium with
EB medium without bFGF and ROCK inhibitor. At day 6, we replaced the medium
with neural induction medium (NIM: DMEM/F12, N2 supplement, Glutamax,
MEM-NEAA, Heparin solution (Merck, Darmstadt, Germany, #H3149-25KU). At
days 8–11, we embedded the formed organoids into Matrigel and kept them in
NIM for 2 days, and in organoid differentiation medium containing 1:1 DMEM/
F12: Neurobasal, N2 supplement, B27 supplement without vitamin A, insulin, 2-
ME solution (Thermo Fisher Scientific, Waltham, MA, USA, #31350-010), Glu-
tamax, MEM-NEAA without retinoic acid (RA) (Sigma-Aldrich, St. Louis, MO,
USA, #R2625-50MG), CHIR 99021 for another 4 days. Next, we transferred the
organoids to ultra-low-attachment 6-well plates (Corning, NY, USA, #3261) and
cultured them on an orbital shaker (80 rpm) in organoid maturation medium
containing 1:1 DMEM/F12: Neurobasal, N2 supplement, B27 supplement with
vitamin A, insulin, 2-ME solution, Glutamax supplement, MEM-NEAA, Sodium
Bicarbonate, Vitamin C solution, 1× chemically defined lipid concentrate (Thermo
Fisher Scientific, Waltham, MA, USA, #11905031), 0.4 mM ascorbic acid, BDNF,
GDNF, cAMP, 20 ng/ml Matrigel, and HEPES. We conducted all experiments
using organoids grown in glucose-containing maturation medium. We analyzed
organoid sizes by measuring the area using ImageJ software. For immunostaining,
each human cerebral organoid was fixed in 4% paraformaldehyde (PFA) (EMS,
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Thermo Fisher Scientific, Waltham, MA, USA, #50980487) overnight at 4 °C,
dehydrated by 40% sucrose in PBS, and embedded in Tissue-Tek® O.C.T.TM
compound (Sakura® Finetek, Netherlands, #25608-930). We cut 12-µm sections
and mounted them onto slides (Thermo Fisher Scientific, Waltham, MA, USA,
#6776214).
Droplet-based single-cell RNA-sequencing (Drop-seq). We carried out single-
cell RNA-sequencing86 for 4w DNs derived from CTL (CTL_NoMut: C1;
SURF1_NoMut: S2_Corr1) and SURF1 (SURF1_Mut: S2), and for D90 brain
organoids derived from CTL (CTL_NoMut: C1; SURF1_NoMut: S2_Corr1) and
SURF1 (SURF1_Mut: S2). All samples were assessed in two independent experi-
ments. For brain organoids, we pooled 3–8 organoids per line per experiment. We
processed raw paired-end scRNA-seq data to generate a digital gene expression
(DGE) matrix using Drop-seq tools v. 2.3.0 with default parameters87. We cen-
trifuged methanol-fixed cells at 3000–5000 × g for 5 min, we rehydrated them in
1 ml PBS plus 0.01% BSA supplemented (Sigma-Aldrich, St. Louis, MO, USA,
#A9576-50ML) with RNAse inhibitors (1 unit/μl RiboLock, Thermo Fisher Sci-
entific, Waltham, MA, USA, #EO0381). We pelleted them and resuspended them
in 0.5 ml PBS plus 0.01% BSA in the presence of RNAse inhibitors. We manually
counted the cells by means of a hemocytometer and we diluted them to a sus-
pension of typically ~200 cells/μl in PBS plus 0.01% BSA. We encapsulated the cells
together with Barcoded microparticles (Barcoded Beads SeqB #Macosko-2011-10;
ChemGenes Corp., Wilmington, MA, USA) using a self-built Drop-seq set up
(Online-Drop-seq-Protocol-v.3.1: http://mccarrolllab.com/dropseq/) as previously
described88. Droplets were broken immediately after collection. We reverse-
transcribed and exonuclease-treated the barcoded beads with captured tran-
scriptomes. We amplified the first-strand cDNA by equally distributing beads from
one run to 24 PCR reactions (50 μl volume; 4+ 9 to 11 cycles). We pooled 20 μl
fractions of each PCR reaction (total= 480 μl), then we double-purified with 0.6×
volumes of AMPure XP beads (Beckman Coulter, Brea, CA, USA). We assessed
amplified cDNA libraries and quantified using a BioAnalyzer High Sensitivity Chip
(Agilent, Santa Clara, CA, USA) and the Qubit dsDNA HS Assay system (Thermo
Fisher Scientific, Waltham, MA, USA, #Q32851). We fragmented 600 pg of each
cDNA library, amplified (12 cycles) them, and indexed them for sequencing with
the Nextera XT v2 DNA sample preparation kit (Illumina, San Diego, CA, USA,
#131-1024) using custom primers enabling 3’-targeted amplification. We purified
the libraries with AMPure XP Beads, quantified them, and sequenced them on
Illumina NextSeq 500 sequencers (Illumina Inc., San Diego, CA, USA), NextSeq
500/550 High Output v2 kit (75 cycles) (Illumina, San Diego, CA, USA, #2002496)
in paired-end mode. We processed raw paired-end scRNA-seq data using Drop-seq
tools v. 2.3.0 with default parameters (https://github.com/broadinstitute/Drop-seq/
releases/tag/v2.3.0) to generate the DGE matrices. We performed alignment to the
hg19 reference genome using STAR v. 2.6.089. We achieved unique mapping for
around 80% of the reads in DNs, and 60–70% of the reads in organoids. We
discarded non-uniquely mapped reads. To distinguish between beads that captured
cellular transcriptomes from those that captured ambient RNA, we sorted barcodes
by decreasing number of reads and picked the inflection point (‘knee’) of the
cumulative fraction of reads plot. We selected the top 1000 barcodes for DNs, the
top 8000 for organoids from S2 and S2_Corr1, and the top 3500 for organoids from
C1. We used Seurat v. 3.1.0 for downstream computational analyses90. To remove
damaged cells, we extracted the percentage of mitochondrial reads and the count of
captured transcripts (nCount_RNA) and removed all barcodes with <400
nCount_RNA or high-percentage of mitochondrial reads (>40% in 2D cultures and
>20% in 3D cultures). We removed barcodes with extremely low mitochondrial
reads (<0.8%) to exclude nuclei. In order to exclude potential doublets, we also
excluded cells with very high nUMI (>5000). For each cell, UMI counts per gene
were normalized and scaled. We performed clustering considering only the top
1000 highly variable genes, as identified by the function “FindVariableGenes”.
Variable genes were then used to perform principal component (PC) analysis. We
selected the PCs to be used for downstream analyses by evaluating the “PCEl-
bowPlot” and the “JackStrawPlot”. We used the first 20 PCs for DNs, and the first
30 PCs for organoids. We identified clusters using the function “FindClusters”,
which exploits a SNN modularity optimization clustering algorithm (at Resolu-
tion=1 for DNs and Resolution=0.6 for organoids). We visualized clusters using
the uniform manifold approximation and projection (UMAP) dimensionality
reduction44. We used the manual inspection of marker genes determined using the
“FindAllMarkers” function for cluster identification. This function determines
which genes, that are expressed in at least three cells, are enriched in every clus-
tering using a Wilcoxon rank-sum test. In DNs, we removed the cluster containing
high level of nuclear marker (MALAT1); in organoids, we removed the cluster
characterized by high expression of hemoglobin genes (HBD and HBB) and
interferon-response genes (e.g., IFIT1). After cluster removal, we performed again
normalization, dimensionality reduction, and clustering. Finally, we assigned each
cell to a cell cycle phase (G1, 2, G2M) using the “CellCycleScore” function and a
published gene set91.
Bulk RNA-sequencing. We carried out ribo-zero total RNA-sequencing for 4w
DNs and 8w DNs derived from CTL (SURF1_NoMut: S2_Corr1) and SURF1
(SURF1_Mut: S2), and for D90 brain organoids derived from CTL (SURF1_No-
Mut: S2_Corr1) and SURF1 (SURF1_Mut: S2). All samples were assessed in three
independent experiments. We used 500 ng of total RNA, where rRNA was depleted
using RNase H-based protocol. We mixed total RNA with 1 μg of a DNA oligo-
nucleotide pool comprising 50-nt long oligonucleotide mix covering the reverse
complement of the entire length of each human rRNA (28S rRNA, 18S rRNA, 16S
rRNA, 5.8S rRNA, 5S rRNA, 12S rRNA), incubated with 1U of RNase H
(Hybridase Thermostable RNase H, #H39500, Epicenter Technologies Pvt. Ltd,
Thane, India), purified using RNA Cleanup XP beads (Agencourt #001298v001,
Beverly, MA, USA), DNase treated using TURBO DNase rigorous treatment
protocol, and purified again with RNA Cleanup XP beads. We fragmented the
rRNA-depleted RNA samples and processed them into strand-specific cDNA
libraries using TruSeq Stranded Total LT Sample Prep Kit (Illumina, San Diego,
CA, USA, #20020596) and then sequenced them on NextSeq 500, High Output Kit,
2 × 76 cycles (Illumina, San Diego, CA, USA, #2002496). We carried out polyA
mRNA-sequencing for 4w and 8w DNs derived from H1, C1, S1, and S2 (all in
biological triplicates). mRNA-seq was performed by BGI using an oligo dT
selection (mRNA enrichment) strategy with oligo dT beads to select mRNA with
polyA tail using BGISEQ-500 with DNB seq technology. We mapped all raw
sequencing reads to the human genome (GRCh38 assembly) using STAR (version
2.6.0c) aligner92. We used the default settings, except out-
FilterMismatchNoverLmax, which was set to 0.05. We counted reads using the
htseq-count tool, version 0.9.193, with gene annotation from GENCODE release
2794. For mRNA-sequencing, we analyzed 8w DNs derived from hESCs (H1), CTL
(CTL_NoMut: C1) and SURF1 (SURF1_Mut: S1, S2) using the same DESeq2
parameters. All samples were assessed using three biological replicates out of three
independent experiments. We summed up read counts for genes expressed in H1,
C1, S1, and S2 across the triplicates. S1 and S2 were treated as disease replicates and
compared to H1 and C1. For total RNA-sequencing, we compared S2 to S2_Corr1.
We performed differential gene expression analysis using the DESeq2 (version
1.20.00) R package95, with default statistical analysis: two-tailed Wald test with
multiple comparisons correction according to Benjamini–Hochberg procedure.
All genes with a false discovery rate (FDR) < 0.05 were considered differentially
expressed. We performed functional enrichment analysis using the gProfileR R
package version 0.6.6, with default settings96. All expressed genes were used as
background.
Proteomics analysis. We carried out label-free quantification (LFQ) proteomics
with sample preparation according to a published protocol with minor
modifications97. We used biological triplicates of 8w DNs derived from CTL
(SURF1_NoMut: S2_Corr1) and SURF1 (SURF1_Mut: S2). We lysed samples
under denaturing conditions in a buffer containing 3M guanidinium chloride
(GdmCl), 5 mM tris(2-carboxyethyl)phosphine, 20 mM chloroacetamide, and 50
mM Tris-HCl pH 8.5. Lysates were denatured at 95 °C for 10 min shaking at 1000
rpm in a thermal shaker and sonicated in a water bath for 10 min. We used a small
aliquot of cell lysate for the BCA assay to quantify the protein concentration. We
diluted the lysates (100 µg proteins) with a dilution buffer containing 10% acet-
onitrile and 25 mM Tris-HCl, pH 8.0, to reach a 1M GdmCl concentration. We
digested proteins with 1 µg LysC (MS grade, Roche, Basel, Switzerland) shaking at
700 rpm at 37 °C for 2 h. We diluted the digestion mixture with the same dilution
buffer to reach 0.5 M GdmCl. We added 1 µg trypsin (MS grade, Roche) and
incubated the digestion mixture at 37 °C overnight in a thermal shaker at 700 rpm.
We used solid-phase extraction (SPE) disc cartridges (C18-SD, Waters, Milford,
MA, USA) for peptide desalting, according to the manufacturer’s instructions. We
reconstituted desalted peptides in 0.1% formic acid in water and further separated
them into four fractions by strong cation exchange chromatography (SCX, 3M
Purification, Meriden, CT, USA). We dried eluates in a SpeedVac, dissolved them
in 20 µl 5% acetonitrile and 2% formic acid in water, briefly vortexed them, and
sonicated them in a water bath for 30 s prior injection to nano-LC-MS. LC-MS/MS
was carried out by nanoflow reverse-phase liquid chromatography (Dionex Ulti-
mate 3000, Thermo Fisher Scientific, Waltham, MA, USA) coupled online to a Q-
Exactive HF Orbitrap mass spectrometer (Thermo Fisher Scientific, Waltham, MA,
USA). Briefly, we performed the LC separation using a PicoFrit analytical column
(75 μm ID × 55-cm long, 15 µm Tip ID; New Objectives, Woburn, MA, USA) in-
house packed with 2.1-µm C18 resin (Reprosil-AQ Pur, Dr. Maisch, Ammerbuch,
Germany). We eluted peptides using a gradient from 3.8 to 40% solvent B in
solvent A over 120 min at 266 nL per minute flow rate. Solvent A was 0.1% formic
acid and solvent B was 79.9% acetonitrile, 20% H2O, 0.1% formic acid. Nanoe-
lectrospray was generated by applying 3.5 kV. A cycle of one full Fourier trans-
formation scan mass spectrum (300−1750 m/z, resolution of 60,000 at m/z 200,
AGC target 1e6) was followed by 12 data-dependent MS/MS scans (resolution of
30,000, AGC target 5e5) with a normalized collision energy of 25 eV. In order to
avoid repeated sequencing of the same peptides, we used a dynamic exclusion
window of 30 s. In addition, we sequenced only peptide charge states between two
to eight. We processed raw MS data with MaxQuant software (v1.6.0.1) and
searched against the human proteome database UniProtKB with 21,074 entries,
released on 12/2018. Parameters of MaxQuant database searching were false-
discovery rate (FDR) of 0.01 for proteins and peptides, a minimum peptide length
of 7 amino acids, a mass tolerance of 4.5 ppm for precursor, and 20 ppm for
fragment ions. We used the function “match between runs”. A maximum of two
missed cleavages was allowed for the tryptic digest. We set cysteine carbamido-
methylation as fixed modification, while N-terminal acetylation and methionine
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oxidation were set as variable modifications. We strictly excluded from further
analysis any contaminants, as well as proteins identified by site modification and
proteins derived from the reversed part of the decoy database. We report the
MaxQuant processed output files, peptide and protein identification, accession
numbers, % sequence coverage of the protein, q-values, and LFQ intensities in
Supplementary Data 6. We performed the correlation analysis of biological repli-
cates and the calculation of significantly different metabolites and proteins using
Perseus (v1.6.5.0). LFQ intensities, originating from at least two different peptides
per protein group, were transformed by log2. We employed only protein groups
with valid values within compared experiments. We carried out statistical analysis
by a two-sample two-tailed t-test with Benjamini–Hochberg (BH, FDR of 0.05)
correction for multiple testing. Significantly regulated metabolites and proteins
between patients and controls were indicated by a plus sign in Supplementary
Data 6. For comprehensive proteome data analyses, we applied gene set enrichment
analysis (GSEA, v2.2.3)98 in order to see, if a priori defined sets of proteins show
statistically significant, concordant differences between mutations and controls. For
GSEA analysis, we used all proteins with ratios calculated by Perseus. We applied
GSEA standard settings, except that the minimum size exclusion was set to 5 and
Reactome v5.2 and KEGG v5.2 were used as gene set databases. The cutoff for
significantly regulated pathways was set to be ≤0.05 p-value and ≤0.05 FDR. We
report the results of the GSEA analysis in Supplementary Data 7. The mass
spectrometry data is deposited in the ProteomeXchange Consortium (http://
proteomecentral.proteomexchange.org) via the PRIDE partner repository99.
Metabolomics analysis and multi-omics integration. We carried out metabolite
extraction and profiling by targeted LC-MS as reported previously100. We har-
vested biological triplicates of 8w DNs derived from CTL (SURF1_NoMut:
S2_Corr1) and SURF1 (SURF1_Mut: S2). We aspirated the culture medium,
quickly rinsed the cells twice with ice-chilled 1x PBS, pelleted the cells, and shock-
freeze them in liquid nitrogen. We extracted the metabolites with methyl tert-
butyl-ether (MTBE), methanol, and water. The remaining protein pellet was used
in BCA protein assay for normalization among samples. We aliquoted the extracts
equally into three tubes for later reconstitution in water, acetonitrile, and 50%
methanol in acetonitrile, respectively. We added to each sample an internal stan-
dard mixture containing chloramphenicol, C13-labeled L-glutamine, L-arginine, L-
proline, L-valine, and uracil (10 µM final concentration). A SpeedVac was used to
dry the aliquots. We dissolved dry residuals in three different solvents: (1) 100 µL
50% acetonitrile in MeOH with 0.1% formic acid, (2) 100 µL MeOH with 0.1%
formic acid for analysis by HILIC column, or (3) 100 µL water, 0.1% formic acid for
C18 column mode. We transferred the supernatants to micro-volume inserts. We
injected 20 µL per run for subsequent LC-MS analysis. Over 400 metabolites were
selected to cover most of the important metabolic pathways in mammals. Since
metabolites are very diverse in their chemical properties, we used two different LC
columns for metabolite separation: Reprosil-PUR C18-AQ (1.9 µm, 120 Å, 150 ×
2mm ID; Dr. Maisch, Ammerbuch, Germany) and zicHILIC (3.5 µm, 100 Å, 150 ×
2.1 mm ID; Merck, Darmstadt, Germany). We used the settings of the LC-MS
instrument, 1290 series UHPLC (Agilent, Santa Clara, CA, USA) online coupled to
a QTrap 6500 (Sciex, Foster City, CA, USA) as reported previously101. The buffer
conditions were A1, 10 mM ammonium acetate, pH 3.5 (adjusted with acetic acid);
B1, 99.9% acetonitrile with 0.1% formic acid; A2, 10 mM ammonium acetate, pH
7.5 (adjusted with ammonia solution); B2, 99.9% methanol with 0.1% formic acid.
We prepared all buffers in LC-MS grade water and organic solvents. We performed
peak integration with MultiQuantTM software v.2.1.1 (Sciex, Foster City, CA,
USA) and reviewed it manually. We normalized peak intensities, first against the
internal standards, and subsequently against protein abundances obtained from the
BCA assay. We used the first transition of each metabolite for relative quantifi-
cation between samples and controls. We carried out statistical analysis with
Perseus (https://www.nature.com/articles/nmeth.3901). We employed a two-
sample two-tailed t-test with Benjamini–Hochberg (BH, FDR of 0.05) correction
for multiple testing without q-value cutoff. All values above the dashed line in
Fig. 4e are significant by this measure. In order to also address the biological
meaning of large ratios between sample means, we calculated a second and inde-
pendent significance cutoff indicated by a solid line in Fig. 4e. This cutoff was based
on an FDR of 0.05, while the minimal fold change s0 was set to 0.1. In this way, if a
metabolite gives a very good p-value but its fold change is below s0, it will not be
considered as significant. Using this approach, we could take into account both the
p-value (0.05) and the difference between the means. We provide the list of all
metabolites including MRM ion ratios, KEGG and HMDB metabolite identifiers,
and statistical values in Supplementary Data 8. These data were obtained using a
previously reported LC-MS method containing the list of metabolites, transitions,
and retention times102. We deposited all original LC-MS generated QTrap wiff files
as well as MultiQuantTM processed peak integration q.session on the peptideatlas
repository (http://www.peptideatlas.org). We performed the integration of total
RNA-sequencing, proteomics, and metabolomics of 8w DNs derived from S2 and
S2_Corr1 using xMWAS, as previously described45.
PCR analyses and nanostring. We performed gene expression analysis by
quantitative real-time RT-PCR (qPCR) using SYBR Green PCR Master Mix
(Thermo Fisher Scientific, Waltham, MA, USA, #4309155) and the ViiATM 7
Real-Time PCR System (Applied Biosystems, Waltham, MA, USA). For each target
gene, we measured cDNA samples and negative controls in triplicates using ABI
PRISMTM 384-Well Clear Optical Reaction Plate (Applied Biosystems/Thermo
Fisher Scientific, Waltham, MA, USA, #4309849). We calculated the relative
transcript levels of each gene based on the 2−ΔΔCT method. We normalized the
data to the housekeeping gene AXTB and presented the results as mean LOG2
ratios in relation to control cell lines. For primer-induced restriction analysis
(PIRA) of S1, the PCR product of 141 bp was cut by SmaI (NEB, Ipswich, MA,
USA, #R0141S) into 23+ 118 bp in the presence of c.530T>G mutation. For PIRA
of S2, the PCR product of 437 bp was cut by AvaII (NEB, Ipswich, MA, USA,
#R0153S) into 292+ 145 bp fragments only in the presence of the mutation c.769G
> A. For PIRA of S2, the PCR product of 550 bp was cut by BbsI (NEB, Ipswich,
MA, USA, #R3539) into 221+ 324 bp fragments only in the presence of the
mutation c.769G>A. For mtDNA copy number quantification, we isolated genomic
DNA (gDNA) using the NucleoSpin Tissue kit (Macherey-Nagel, Düren, Germany,
#740952.50). We amplified the purified gDNA using the primer pairs for MT-ND1
(mtDNA-encoded gene of CI) and NDUFV1 (single-copy nuclear-encoded gene of
CI) and visualized with a gel imager (VWR). We used a MicroAmp Optical
96-Well reaction plate (Applied Biosystems/Thermo Fisher Scientific, Waltham,
MA, USA, #4316813) based on the SYBR Green protocol on an ABI Prism
7000 sequence detection system. We used the ABI 7000 system SDS software to
analyze the amplification curves103. As MT-ND1 is encoded by the mtDNA and
NDUFV1 is encoded by the nuclear DNA, the ratio MT-ND1/NDUFV1*2
(mtDNA/gDNA) equals mtDNA copy number per cell104, providing an indirect
measure of the abundance of mitochondria per cell. All primer sequences are
reported in Supplementary Data 12. We performed Nanostring-based differential
expression analyses of mRNA expression using custom-designed 72-plex Nano-
string nCounterTM probes panel. The mRNA transcript quantification analysis,
including sample preparation protocol, hybridization, and detection was performed
according to manufacturer’s recommendations.
Immunostaining. We fixed cells grown on Matrigel-coated coverslips with 4% PFA
for 20 min at room temperature (RT) and washed two times with PBS. For per-
meabilization, we incubated the fixed cells with a blocking solution containing 10%
normal donkey serum (DNS) (Merck Millipore, Burlington, MA, USA, #S30-
100ML) and 1% Triton X-100 (Sigma-Aldrich, St. Louis, MO, USA, #T8787) in
PBS with 0.05% Tween 20 (Sigma-Aldrich, St. Louis, MO, USA, #P9416) (PBS-T)
for 1 h at RT. We diluted primary antibodies in blocking solution and incubated
them overnight at 4 °C on a shaker. Primary antibodies used were as follows: PAX6
(BioLegend, San Diego, CA, USA, #901301; 1:200), SOX2 (Santa Cruz, Dallas, TX,
USA, #sc-17320; 1:100), TUJ1 (Sigma-Aldrich, St. Louis, MO, USA, #T8578;
1:3000), LIN28 (ProteinTech Europe, Manchaster, UK, #11724; 1:300), TRA-1-60
(Millipore, Burlington, MA, USA, MAB4360; 1:200), MAP2 (Synaptic System,
Göttingen, Germany, #188 004; 1:100), GFAP (Synaptic Systems, Göttingen,
Germany, #173004; 1:500), NANOG (R&D Systems, Minneapolis, MN, USA,
#AF1997; 1:200), smooth muscle actin (SMA) (DakoCytomation, Glostrup, Den-
mark, #M0851; 1:200), SOX17 (R&D Systems, Minneapolis, MN, USA, #AF1924;
1:50), TH (Millipore, Burlington, MA, USA, #AB152; 1:300), FOXA2 (Seven Hills
Bioreagents, Cincinnati, OH, USA, # WRAB 1200; 1:100), S100ß (Abcam, Cam-
bridge, UK, #14849; 1:500), SYP (Sigma-Aldrich, St. Louis, MO, USA, #SVP-38;
1:500), SYN (Invitrogen/Thermo Fisher Scientific, Waltham, MA, USA, #A-6442,
1:100), VAMP2 (Synaptic Systems, Göttingen, Germany, #104211; 1:500), NESTIN
(Millipore, Burlington, MA, USA, #MAB5326; 1:200), NURR1 (Sigma-Aldrich, St.
Louis, MO, USA, N4663; 1:500), pVIM (MBL Life Science, Woburn, MA, USA,
#D095-3; 1:1000). Corresponding secondary antibodies (all Alexa Fluor, 1:2000,
Life Technologies/Thermo Fisher Scientific, Waltham, MA, USA) were diluted in
blocking solution for 1 h at RT on a shaker. Counterstaining of nuclei was carried
out using 1:10,000 Hoechst (Invitrogen/Thermo Fisher Scientific, Waltham, MA,
USA, #H3570). We acquired the images of 2D cultures using the confocal
microscope LSM510 Meta (Zeiss, Jena, Germany) in combination with the Axio-
Vision V4.6.3.0 software (Zeiss, Jena, Germany) and further processed with
AxioVision software and ImageJ. We acquired images of 3D organoids using a
Keyence bz-x710 (Osaka, Japan) microscope.
Immunoblotting. We lysed NPCs in RIPA buffer (150 mM NaCl, 5 mM EDTA, 50
mM Tris, 1% NP-40, 0.5% sodium deoxycholate and 0.1% SDS) in the presence of
protease and phosphatase inhibitors. We incubated the samples on ice for 30 min
and centrifuged at 14,000 × g for 20 min at 4 °C. We determined protein con-
centration using the PierceTM BCA assay (Thermo Fisher Scientific, Waltham,
MA, USA, #23225). For MT-CO2 immunoblot, we loaded 120 µg proteins on
NuPAGE Novex 4–12% Bis-Tris precast SDS-PAGE gels (Invitrogen/Thermo
Fisher Scientific, Waltham, MA, USA, #NP0326BOX). For PGC1A immunoblot,
we loaded 40 μg of proteins in a 4–12% SDS-PAGE. We transferred the gels onto
Immobilin-FL PVDF membranes (Merck Millipore, Burlington, MA, USA,
#IPFL00010). We used the following primary antibodies: MT-CO2 (Abcam,
Cambridge, UK, ab110258; 1:1500), beta-actin (ACTB; Sigma-Aldrich, St. Louis,
MO, USA, #A5316; 1:4000), PGC1A (Novus Biological, Centennial, CO, USA,
#NBP1-04676; 1:1000), and GAPDH (Immunological Sciences, Rome, Italy,
#MAB-10578; 1:1000). For MT-CO2 immunoblots, we measured chemilumines-
cence in a Fujifilm LAS‐3000 (Fujifilm, Tokyo, Japan) after the addition of Pierce
ECL Western Blotting Substrate (Thermo Fisher Scientific, Waltham, MA, USA).
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For PGC1A immunoblots, we acquired the images using the ChemiDoc Imaging
System apparatus (Bio-Rad Laboratories, Milan, Italy) and analyzed them with
Image LabTM software, version 6.0.1 for Windows (Bio-Rad Laboratories, Milan,
Italy). Blue-native gel electrophoresis (BNGE) was performed as described105. We
solubilized mitoplasts from NPCs derived from C1 and C1_Mut1 using n-dodecyl-
b-d-maltoside (DDM) at 1% final concentration. We separated samples by elec-
trophoresis using precast NativePAGE 4–16% Bis-Tris gels (Invitrogen/Thermo
Fisher Scientific, Waltham, MA, USA, #BN1001BOX) followed by a second,
denaturing electrophoresis using precast NuPAGETM 4–12% Bis-Tris Protein
Gels, 2D-well (Invitrogen/Thermo Fisher Scientific, Waltham, MA, USA,
#NP0326BOX). We transferred the samples onto a nitrocellulose membrane and
immunoblotted using the OXPHOS rodent antibody cocktail (containing a cocktail
of five antibodies: SDHB, UQCRC2, MT-CO1, ATP5A, and NDUFB8) (Abcam,
Cambridge, UK, #ab110413), COX4I1 antibody (Invitrogen/Thermo Fisher Sci-
entific, Waltham, MA, USA, #A21347), and SDHA antibody (Abcam, Cambridge,
UK, #ab14715). We performed chemiluminescence-based immunostaining
(Amersham ECL Western Blotting Detection Kit, #RPN2108, Cytiva, Marlborough,
MA, USA). We acquired the images with ChemiDoc Imaging System apparatus
(Bio-Rad Laboratories, Milan, Italy) and analyzed them with Image LabTM soft-
ware, version 6.0.1 for Windows (Bio-Rad Laboratories, Milan, Italy).
Detection of in situ COX enzyme activity. We assessed the activities of cyto-
chrome c oxidase (COX) for CIV and of succinate dehydrogenase (SDH) for CII
using an in situ enzymatic colorimetric-based assay on NPCs derived from CTL
(CTL_NoMut: C1, C2, C3; SURF1_NoMut: S2_Corr1) and SURF1 (SURF1_Mut:
S1, S2; CTL_Mut: C1_Corr1). We performed enzyme histochemical staining using
standard procedures106. After gentle centrifugation, we transferred the samples on
Tissue Tek® on a cork plate and shock frozen them in isopentane precooled in
liquid nitrogen. We generated 10-µm-thick cryosections and stained them with
SDH (Abcam, Cambridge, UK, #Ab14715), COX and hematoxylin-eosin (HE) for
visualization of the cells. For quantification of the enzyme activity, we visualized
stained cryosections with Leica DMI6000 microscope (×10) (Leica Microsystems,
Wetzlar, Germany) and took pictures using a Moticam 2500 (5.0 M Pixel) (Motic,
Speed Fair Co., Ltd, Hong Kong, China) with the software Motic Images Plus 2.0.
We analyzed the images using the software MBF ImageJ bundle (formerly WCIF
ImageJ). The final average gray value per region of interest represented the
intensity of the brown DAB deposits in the mitochondrial matrix and thereby the
COX activity of different samples.
Bioenergetic profiling. We performed live-cell assessment of cellular bioenergetics
using Seahorse XF96 extracellular flux analyzer (Agilent Technologies, Santa Clara,
CA, USA), as described previously31. All experiments were conducted using cells
grown in glucose-containing medium. Briefly, we plated 20,000 cells onto each
Matrigel-coated well of XF96-well plates (Agilent Technologies, Santa Clara, CA,
USA, #101085-004). We maintained NPCs in the plates for 2 days and DNs cul-
tures for 4 or 8 weeks. Brain organoids were dissociated using Worthington papain
solution and 20,000 cells were plated onto each Matrigel-coated well of XF96-well
plates. On the assay day, we incubated all the cells at 37 °C 5% CO2 for 60 min to
allow media temperature and pH to reach equilibrium. We measured simulta-
neously mitochondrial respiration (oxygen consumption rate, OCR) and anaerobic
glycolysis (extracellular acidification rate, ECAR) using the sequential introduction
of oligomycin (Sigma-Aldrich, St. Louis, MO, USA, #579-13-5, FCCP (Sigma-
Aldrich, St. Louis, MO, USA, #C2920-10MG), and then rotenone (Sigma-Aldrich,
St. Louis, MO, #83-794) plus antimycin A (Sigma-Aldrich, St. Louis, MO, USA,
#1397-94-0) (all products at 1 µM). The addition of these drugs allowed us to
calculate: basal OCR level, basal ECAR level, maximal respiration, and ATP pro-
duction, as described in detail before107. We normalized the values based on the
DNA content in each well of the plate quantified using CyQUANT kit (Molecular
Probes/Thermo Fisher Scientific, Waltham, MA, USA, #C7026). We collected the
supernatants from the XF96-well plates and used them to quantify the lactate
amount with a Lactate Fluorometric Assay Kit (BioVision, Milpitas, CA, USA,
#7K607-100).
High-content analysis (HCA) of neuronal morphogenesis. We employed HCA
to quantify the neuronal branching outgrowth and complexity using CellInsight
CX7 microscope (Thermo Fisher Scientific, Waltham, MA, USA). Briefly, we split
NPCs or DNs at 4 or 8 weeks of differentiation using Accutase and seeded them at
a density of 10,000 cells/well on Matrigel-coated 96-well plates with black-wall and
clear-bottom (Corning, Corning, NY, USA, #353219). We then stained the cells
with TUJ1 antibody (Sigma-Aldrich, St. Louis, MO, USA, #T8578; 1:3000) using
4% PFA (EMS, Thermo Fisher Scientific, Waltham, MA, USA, #50980487) for 20
min at RT and washed two times with PBS. For permeabilization, we incubated the
fixed cells with a blocking solution containing 10% normal donkey serum (DNS)
and 1% Triton X-100 (Sigma-Aldrich, St. Louis, MO, USA, #T8787) in PBS with
0.05% Tween 20 (Sigma-Aldrich, St. Louis, MO, USA, #P9416) (PBS-T) for 1 h at
RT. We diluted primary antibodies in blocking solution, incubated them overnight
at 4 °C on a shaker, and performed counterstaining with Hoechst. The morpho-
genesis of TUJ1-positive cells within NPCs or DN cultures were quantified using
the “Cellomics Neuronal Profiling v4 BioApplication” (CellInsight CX7, High
Content Platform, Thermo Fisher Scientific, Waltham, MA, USA). We used a
similar HCA-based approach to quantify the number of TUJ1-positive neurons and
TH-positive neurons within DNs.
Mitochondrial morphology and functionality. For visualization of mitochondrial
morphology in NPCs derived from C1, C2, S1, S2, S2_Corr1, _Corr2, we used
transmission electron microscope (TEM). Ultrastructural analysis was performed
after fixation of the cells in 2.5% glutaraldehyde for 48 h at 4 °C, post-fixation in 1%
osmium tetroxide, and sample embedding in Araldite. Semi-thin sections were used
to identify viable and characteristic cells and respective ultrathin sections were
stained with uranyl acetate and lead citrate. A P902 electron microscope (Zeiss,
Oberkochem, Germany) was used to analyze the specimens. For mitochondrial
membrane potential (MMP) quantification, we used an HCA-based live-cell
detection assay that we previously described31. Briefly, we split NDUFS4 NPCs and
CTL NPCs with Accutase isolation and seeded them on a black-wall, clear-bottom
plate coated with Matrigel at a density of 40,000 or 80,000 cells/well on 96-well
plates (Corning, Corning, NY, USA, #353219) and incubated in NPC medium
overnight at 37 °C, 5% CO2. On the day of the assay, we live-stained NPCs with
10 nM TMRM (Molecular Probes, Life Technologies, Waltham, MA, USA, #T668),
a potentiometric dye that accumulates in active mitochondria, for 30min at 37 °C
and 5% CO2. We performed a control staining in parallel by exposing cells to 1 mM
FCCP (Sigma-Aldrich, St. Louis, MO, USA, #C2920-10MG) and 1mM antimycin A
(Sigma-Aldrich, St. Louis, MO, USA, #1397-94-0) to cause complete mitochondrial
depolarization. We then washed all cells with PBS and stained them with 1:10,000
Hoechst (33342, Invitrogen/Thermo Fisher Scientific, Waltham, MA, USA, #H3570)
diluted in phenol red-free-DMEM (Gibco/Thermo Fisher Scientific, Waltham, MA,
USA, #A1443001) for 10 min at RT. After additional PBS washes, we kept the cells
in phenol red-free-DMEM for the duration of the assay. We imaged and analyzed
the live-cells using the CellInsight CX7 microscope (Thermo Fisher Scientific,
Waltham, MA, USA). For quantification of mitochondrial ROS, we seeded 250,000
NPCs per well a 24-well plate and incubated at 37 °C and 5% CO2 until they reached
70–90% confluency. We used 3 µM antimycin A for 1 h to induce ROS production
by blocking CIII. After one washing step with DPBS, we incubated the cells with
3.5 µM superoxide indicator MitoSOX (Invitrogen/Thermo Fisher Scientific,
Waltham, MA, USA, #M36008) for 20–30min at 37 °C and 5% CO2. Within
mitochondria, MitoSOX is oxidized by ROS resulting in red fluorescence (510/580
nm). We harvested the cells using Accutase and pelleted them in DPBS containing
DAPI (1 µg/µL). We then carried out fluorescence-activated cell sorting (FACS)
analysis to quantify the MitoSOX and DAPI signals using the LSRFortessa cell
analyzer (BD, Franklin Lakes, NJ, USA). To assess proliferation, we seeded NPCs at
a density of 5000, 20,000, and 40,000 cells/well onto Matrigel-coated black-wall,
clear-bottom plates (Corning, NY, USA, #353219). We used two plates for samples
that we fixed at 24 h distance. After fixation for 20min in 4% PFA and 8.1 µM
Hoechst, we washed the plates with PBS and analyzed their fluorescence intensity
with a Tecan plate reader (Infinite M200, Tecan, Zürich, Switzerland).
Electrophysiology. To analyze passive and active membrane properties and
spiking and synaptic activity, we carried out whole-cell patch-clamp recordings on
DNs at 4, 6, and 8 weeks of differentiation. We visualized the cells at RT under
phase contrast optics on an upright microscope (Axioskop, Zeiss, Germany) using
a ×63/0.95 water immersion objective. We performed recordings with a patch-
clamp amplifier (EPC-9, HEKA Electronics, Lambrecht, Germany). We filled
recording pipettes with an intracellular solution containing (in mM): 4 NaCl, 120
KCl, 5 EGTA, 10 HEPES, 5 glucose, 4 MgCl2, 0.5 CaCl2 (pH 7.3, 270 mOsmol/kg).
The pipette to bath resistance ranged from 5 to 7MOhm. We applied series
resistance compensation as much as possible (50–70%). The effective series resis-
tance was in the range of 20–40MOhm and was checked throughout the whole
experiment by using a short depolarizing pulse (10 mV, 20 ms). We accepted
recordings only if the series resistance was less than 40 MOhm. Bath solution
contained (in mM): 136 NaCl, 2.5 KCl, 20 glucose, 20 HEPES, 2 CaCl2, 1 MgCl2
(pH 7.3, 305 mOsmol/kg). We estimated whole-cell input resistance on the basis of
passive current responses to moderate depolarizing voltage pulses of short duration
(±10 mV for 20 ms). We estimated whole-cell membrane capacitance by integra-
tion of the capacitive current transient and division by the respective stimulation
voltage. We elicited voltage-gated Na+- and K+-currents by a series of 200 ms
depolarizing pulses applied from the holding potential of −70 mV, in 10 mV
increments between −70 and +70 mV. Passive responses were subtracted by using
a hyperpolarizing pulse of −20 mV. We recorded spontaneous synaptic currents in
voltage-clamp mode at a holding potential of −70 mV without specific blockers. To
evaluate action potential generation and discharge properties, we adjusted the cells
to −90 mV by steady current injection and depolarized them by injection of
positive current pulses (5–50 pA) of 1 s duration under current-clamp conditions.
We acquired the signals at a rate of 10 kHz and analyzed using WinTida 5.0
(HEKA Electronics, Lambrecht, Germany).
SURF1 gene augmentation. We generated lentiviral plasmids expressing SURF1
(amino acid sequence NP_003163.1) and GFP derivative mCitrine using the
GatewayTM cloning system108. We shuttled open reading frames from entry
vectors encoding mCitrine or SURF1 protein (entry clone id: RZPDo839E0486)
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into a lentiviral vector harboring a phosphoglycerate kinase (PGK) promoter
(pLenti PGK Neo DEST (w531-1). The destination vector was a gift from Eric
Campeau & Paul Kaufman (Addgene, Watertown, MA, #19067; http://n2t.net/
addgene:19067; RRID: Addgene_19067)109. We additionally generated AAV plas-
mids expressing SURF1 and mCitrine. Therefore, we shuttled the open reading
frames of mCitrine and SURF1, respectively, into an AAV destination vector
harboring the chicken β-actin promoter (CAG) promoter (pAAV-Gateway). The
destination vector was a gift from Matthew Nolan (Addgene, Watertown, MA,
#32671; http://n2t.net/addgene:32671; RRID: Addgene #32671)110. The prepara-
tion of lentiviral and AAV serotype 9 (AAV9) particles was performed by the Viral
Core Facility of the Charité Berlin as previously described111. For lentiviral
transduction, we seeded NPCs onto 6-well plates at a concentration of ~500,000
cells per well. The next day, we transduced the cells with viruses expressing either
mCitrine or WT-SURF1. We used a titer of 1.85E+ 08 particles per ml for mCi-
trine and 1.32E+ 08 particles per ml for WT-SURF1. One day later, we changed
the medium kept the cells for 2 days in the incubator. Then, we carried out
antibiotic selection using 500 µg per ml of geneticin (G418; Gibco/Thermo Fisher
Scientific, Waltham, MA, USA, #10131027) for 5 days according to the related
killing curves. We established a stable line and let them differentiate into 4w DNs
for conducting experiments. For AAV9 transduction, we seeded NPCs or 4w DNs
on a seahorse or HCA plate at a concentration of ~12,000 cells per well. The next
day, we transduced the cells with viruses expressing either mCitrine or WT-SURF1.
We used a titer of 1.32E+ 12 particles per ml for mCitrine and 6.55E+ 11 particles
per ml for WT-SURF1. We transduced the cells 2 days prior to assay day and one
day later, we changed the medium to maintain the cells in the incubator until the
assay day.
Treatment strategies. For hypoxia treatment, we exposed NPCs or 8w DNs to 5%
oxygen overnight. The day after, we assessed their bioenergetic profiling and HCA
neuronal profiling. We used the following drugs on SURF1 NPCs: α-tocotrienol
(AT3) (Cayman Chemical, Ann Arbor, MI, USA, #922500), n-acetyl cysteine
(NAC) (Sigma-Aldrich, St. Louis, MO, USA, #A7250), ascorbic acid (AA) (Sigma-
Aldrich, St. Louis, MO, USA, #A92902), dihydrolipoic acid (DHLA) (Sigma-
Aldrich, St. Louis, MO, USA, #T8260), increased glucose, and pyruvate supple-
mentation. We treated SURF1 NPCs ON with bezafibrate (Selleckchem, Houston,
TX, USA, #S4159). For lentiviral-mediated PGC1A overexpression, we first
obtained the PGC1A open reading from the pcDNA4 myc PGC1A plasmid, which
was a gift from Toren Finkel (Addgene, Watertown, MA, #10974; http://n2t.net/
addgene:10974; RRID: Addgene_10974). We amplified the PGC1A open reading
frame using overhang forward and reverse primers reported in Supplementary
Data 12. We introduced a stop codon at the C-terminus and GatewayTM-
compatible BP sites flanking the open reading frame. The resulting PCR product
was cloned using BP Clonase (Invitrogen, Thermo Fisher Scientific, Waltham, MA,
USA) into a pDONR221 entry plasmid, which was subsequently used to shuttle the
PGC1A open reading frame into the pLenti PGK Neo DEST vector using LR
Clonase (Invitrogen, Thermo Fisher Scientific, Waltham, MA, USA). The resulting
plasmid was analyzed by restriction enzyme digest with BsrGI and sequence
identity was confirmed by Sanger sequencing. The preparation of lentiviral parti-
cles was performed by the Viral Core Facility of the Charité Berlin as previously
described111. We transduced the viral particles on SURF1 NPCs (SURF1_Mut: S1,
S2) following the procedure described for SURF1 gene augmentation.
Statistics and reproducibility. We analyzed the data using GraphPad Prism 8.0
(GraphPad Software, Inc.) and employed R environment for statistical computing.
For all datasets, we tested the normality of the distribution using GraphPad Prism.
Unless otherwise indicated, we expressed the data as mean and standard error of
the mean (mean ± s.e.m.). P values below 0.05 were considered significant. We
performed outlier test analysis to identify potential outliers using GraphPad Prism
(www.graphpad.com/quickcalcs/Grubbs1.cfm). The data are presented as scatter
plots with individual data points showing all individual measurements. We carried
out all experiments using at least three biological replicates over different inde-
pendent experiments. In all respective figures legends, we report the exact number
of biological replicates and independent experiments. We assessed statistical sig-
nificance using parametric tests (Student’s t-test, ANOVA) for normally-
distributed data and non-parametric tests (two-sided Mann–Whitney U test,
Kruskal–Wallis) when normal distribution could not be verified. The statistical
details of the experiments can be found in the respective figure legends.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
There are restrictions to the availability of the patient-derived iPSC lines generated in this
study due to the nature of our ethical approval that does not support sharing to third
parties without a specific amendment and does not allow to perform genomic studies to
respect the European privacy protection law. The datasets generated during this study are
available, in case data protection laws did not prevent the original datasets from being
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(GEO) database, accession number: GSE152915. RNA-sequencing dataset: deposited in
GEO database, accession number: GSE126360. Proteomics dataset: deposited in the
ProteomeXchange Consortium server, project accession: PXD019112. Metabolomics
dataset: deposited in PeptideAtlas, identifier: PASS01598. Source data are provided with
this paper.
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